RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions

Abstract

RNA interference is provided for inhibition of tumor necrosis factor .alpha. (TNF.alpha.) by silencing TNF.alpha. cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF.alpha. converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF.alpha. targets, in particular, is useful for treating patients having a TNF.alpha.-related condition or at risk of developing a TNF.alpha.-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.

Description

RELATED APPLICATIONS

[0001] The present application is a continuation application of U.S. patent application Ser. No. 14/244,623, filed 3 Apr. 2014 (pending), which is a divisional application of U.S. patent application Ser. No. 13/973,176 filed Aug. 22, 2013 (abandoned), which is a divisional application of U.S. patent application Ser. No. 13/035,147 filed Feb. 25, 2011 (now U.S. Pat. No. 8,541,389), which is a divisional application of U.S. patent application Ser. No. 12/700,188 filed 4 Feb. 2010 (abandoned), which is a divisional application of U.S. patent application Ser. No. 11/750,262 filed 17 May 2007 (now U.S. Pat. No. 7,732,421), which claims benefit to U.S. Provisional Patent Application Ser. No. 60/801,788 filed on 19 May 2006, titled RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR .alpha.-RELATED CONDITIONS, the text of which is specifically incorporated by reference herein.

FIELD OF THE INVENTION

[0002] The present invention relates to the field of interfering RNA compositions for silencing tumor necrosis factor .alpha. (TNF.alpha.) by silencing the TNF.alpha. cell surface receptor TNF receptor-1 (TNFR1) mRNA, or the TNF.alpha. converting enzyme (TACE/ADAM17) mRNA. Silencing such TNF.alpha. targets is useful for treatment of patients having a TNF.alpha.-related condition or at risk of developing such a condition.

BACKGROUND OF THE INVENTION

[0003] Inflammation is generally treated with a standard anti-inflammatory regimen that includes steroids and/or non-steroidal anti-inflammatory drugs (NSAIDS). Allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, and asthma have historically been treated with a regimen of oral, intranasal or topical antihistamines in addition to or oral or intranasal steroids. Systemic treatment typically requires higher concentrations of the drug compound to be administered to afford an effective concentration to reach the necessary treatment site. Antihistamine compounds are known to have central nervous system activity; drowsiness and drying of mucus membranes are a common side-effect of antihistamine use. Steroids and NSAIDS have potential side effects including intraocular pressure increase, cataract, glaucoma or corneal melting.

[0004] Dry eye, also known as conjunctivitis sicca or keratoconjunctivitis sicca, is a common ophthalmological disorder involving breakdown of the pre-ocular tear film, resulting in dehydration of the exposed outer surface of the eye. To date, dry eye has been treated with topical administration of artificial tear solutions. Some of these solutions contain mucomimetic substances to temporarily replace or replenish the mucin layer in mucin deficient patients. Use of methylprednisolone has been proposed in a short-term "pulse" treatment to treat exacerbations of dry eye. The proposed "pulse" therapy is required to avoid complications associated with traditional steroid therapy for inflammatory conditions such as increased intraocular pressure and cataract formation.

[0005] The cytokine TNF.alpha. is a target for anti-inflammatory therapy of dry eye and uveitis. In a rabbit model of lacrimal gland inflammation-induced dry eye, inhibition of corneal staining and restoration of tear breakup time has been achieved by specific modulation of ocular surface TNF.alpha. levels. Dry eye therapy resulted by inhibiting TNF.alpha. synthesis (RDP58) or by specifically neutralizing TNF.alpha. using a monoclonal antibody (REMICADE.RTM.) or a soluble receptor (ENBREL.RTM.). Each of these TNF.alpha. directed treatments resulted in levels of efficacy obtained with topical ocular anti-inflammatory steroids.

[0006] U.S. Patent Publication 2005/0227935, published Oct. 13, 2005, to McSwiggen et al. relates to RNA interference mediated inhibition of TNF and TNF receptor gene expression. However, said publication teaches none of the particular target sequences for RNA interference as provided herein.

[0007] Embodiments of the present invention address the need in the art for further agents and treatment methods for dry eye and inflammation and provide alternative therapies therefor.

SUMMARY OF THE INVENTION

[0008] Embodiments of the present invention provide highly potent and efficacious treatment, prevention or intervention of a TNF.alpha.-related condition without side effects associated with steroids or NSAIDS. In one aspect, methods of the invention include treating a subject having a TNF.alpha.-related condition or at risk of developing a TNF.alpha.-related condition by administering interfering RNAs that silence expression of TACE mRNA or TNFR1 mRNA, thus interfering with proteolytic processing of the precursor to TNF.alpha., or interfering with binding of TNF.alpha. to its cell surface receptor, respectively, thereby attenuating activity of TNF.alpha. and preventing a cascade of events related to apoptosis and inflammation.

[0009] A TNF.alpha.-related condition includes conditions such as dry eye and TNF.alpha.-related inflammatory conditions. A TNF.alpha.-related inflammatory condition includes conditions such as ocular inflammation, allergic conjunctivitis, dermatitis, rhinitis, and asthma, for example, and includes those cellular changes resulting from the activity of TNF.alpha. that leads directly or indirectly to the TNF.alpha.-related inflammatory condition. A TNF.alpha.-related condition particularly includes TNF.alpha.-related ocular conditions such as dry eye, allergic conjunctivitis, and ocular inflammation. The interfering RNA provided herein provides for silencing the TNF.alpha. targets TACE mRNA or TNFR1 mRNA while avoiding undesirable side effects due to nonspecific agents.

[0010] A method of attenuating expression of TACE mRNA of the subject is an embodiment of the invention. The method comprises administering to the subject a composition comprising an effective amount of interfering RNA having a length of 19 to 49 nucleotides and a pharmaceutically acceptable carrier, the interfering RNA comprising a region of at least 13 contiguous nucleotides having at least 90% sequence complementarity to, or at least 90% sequence identity with, the penultimate 13 nucleotides of the 3' end of an mRNA corresponding to any one of SEQ ID NO:3, SEQ ID NO:14-SEQ ID NO:58, and SEQ ID NO:155-SEQ ID NO:201. The expression of TACE mRNA is attenuated thereby.

[0011] A method of treating a TNF.alpha.-related condition in a subject in need thereof is an embodiment of the invention. The method comprises administering to the subject a composition comprising an effective amount of interfering RNA having a length of 19 to 49 nucleotides, and a pharmaceutically acceptable carrier, wherein the interfering RNA comprises a region of at least 13 contiguous nucleotides having at least 90% sequence complementarity to, or at least 90% sequence identity with, the penultimate 13 nucleotides of the 3' end of an mRNA corresponding to any one of SEQ ID NO:3, SEQ ID NO:14-SEQ ID NO:58, and SEQ ID NO:155-SEQ ID NO:201. The TNF.alpha.-related condition is treated thereby.

[0012] In yet another embodiment of the invention, a method of attenuating activity of TNF.alpha. of a subject by attenuating expression of TACE mRNA or TNFR1 mRNA of the subject comprises administering to the subject a composition comprising an effective amount of interfering RNA having a length of 19 to 49 nucleotides and a pharmaceutically acceptable carrier and the interfering RNA comprises a sense nucleotide strand, an antisense nucleotide strand, and a region of at least near-perfect contiguous complementarity of at least 19 nucleotides where the antisense strand hybridizes under physiological conditions to a portion of mRNA corresponding to SEQ ID NO:1 comprising nucleotide 297, 333, 334, 335, 434, 470, 493, 547, 570, 573, 618, 649, 689, 755, 842, 844, 846, 860, 878, 894, 900, 909, 910, 913, 942, 970, 984, 1002, 1010, 1053, 1064, 1137, 1162, 1215, 1330, 1334, 1340, 1386, 1393, 1428, 1505, 1508, 1541, 1553, 1557, 1591, 1592, 1593, 1597, 1604, 1605, 1626, 1632, 1658, 1661, 1691, 1794, 1856, 1945, 1946, 1947, 1958, 2022, 2094, 2100, 2121, 2263, 2277, 2347, 2349, 2549, 2578, 2595, 2606, 2608, 2629, 2639, 2764, 2766, 2767, 2769, 3027, 3028, 3261, 3264, 3284, 3313, 3317, 3332, or 3337 or where the antisense strand hybridizes under physiological conditions to a portion of mRNA corresponding to SEQ ID NO:2 beginning at nucleotide 124, 328, 387, 391, 393, 395, 406, 421, 423, 444, 447, 455, 459, 460, 467, 469, 470, 471, 475, 479, 513, 517, 531, 543, 556, 576, 587, 588, 589, 595, 601, 602, 611, 612, 651, 664, 667, 668, 669, 677, 678, 785, 786, 788, 791, 792, 804, 813, 824, 838, 843, 877, 884, 929, 959, 960, 961, 963, 964, 965, 970, 973, 974, 1000, 1002, 1013, 1026, 1053, 1056, 1057, 1058, 1161, 1315, 1318, 1324, 1357, 1360, 1383, 1393, 1420, 1471, 1573, 1671, 2044, 2045, 2046, 2047, 2048, 2089, 2090, 2091, 2092, or 2098. The expression of TACE mRNA is attenuated in those embodiments where the antisense stand hybridizes to a portion of mRNA corresponding to SEQ ID NO:1 as cited above. The expression of TNFR1 mRNA is attenuated in those embodiments where the antisense stand hybridizes to a portion of mRNA corresponding to SEQ ID NO:2 as cited above.

[0013] A method of treating a TNF.alpha.-related condition in a subject in need thereof is an embodiment of the invention, the method comprising administering to the subject a composition comprising an effective amount of interfering RNA having a length of 19 to 49 nucleotides, and a pharmaceutically acceptable carrier, the interfering RNA comprising a sense nucleotide strand, an antisense nucleotide strand, and a region of at least near-perfect contiguous complementarity of at least 19 nucleotides; wherein the antisense strand hybridizes under physiological conditions to a portion of mRNA corresponding to SEQ ID NO:1 comprising nucleotide 297, 333, 334, 335, 434, 470, 493, 547, 570, 573, 618, 649, 689, 755, 842, 844, 846, 860, 878, 894, 900, 909, 910, 913, 942, 970, 984, 1002, 1010, 1053, 1064, 1137, 1162, 1215, 1330, 1334, 1340, 1386, 1393, 1428, 1505, 1508, 1541, 1553, 1557, 1591, 1592, 1593, 1597, 1604, 1605, 1626, 1632, 1658, 1661, 1691, 1794, 1856, 1945, 1946, 1947, 1958, 2022, 2094, 2100, 2121, 2263, 2277, 2347, 2349, 2549, 2578, 2595, 2606, 2608, 2629, 2639, 2764, 2766, 2767, 2769, 3027, 3028, 3261, 3264, 3284, 3313, 3317, 3332, or 3337. The TNF.alpha.-related condition is treated thereby.

[0014] A method of treating a TNF.alpha.-related ocular condition in a subject in need thereof is an embodiment of the invention, the method comprising administering to the subject a composition comprising an effective amount of interfering RNA having a length of 19 to 49 nucleotides, and a pharmaceutically acceptable carrier, the interfering RNA comprising a sense nucleotide strand, an antisense nucleotide strand, and a region of at least near-perfect contiguous complementarity of at least 19 nucleotides; wherein the antisense strand hybridizes under physiological conditions to a portion of mRNA corresponding to SEQ ID NO:2 comprising nucleotide 124, 328, 387, 391, 393, 395, 406, 421, 423, 444, 447, 455, 459, 460, 467, 469, 470, 471, 475, 479, 513, 517, 531, 543, 556, 576, 587, 588, 589, 595, 601, 602, 611, 612, 651, 664, 667, 668, 669, 677, 678, 785, 786, 788, 791, 792, 804, 813, 824, 838, 843, 877, 884, 929, 959, 960, 961, 963, 964, 965, 970, 973, 974, 1000, 1002, 1013, 1026, 1053, 1056, 1057, 1058, 1161, 1315, 1318, 1324, 1357, 1360, 1383, 1393, 1420, 1471, 1573, 1671, 2044, 2045, 2046, 2047, 2048, 2089, 2090, 2091, 2092, or 2098. The TNF.alpha.-related condition is treated thereby.

[0015] A second interfering RNA having a length of 19 to 49 nucleotides could also be administered to the subject in a further embodiment; the second interfering RNA comprising a sense nucleotide strand, an antisense nucleotide strand, and a region of at least near-perfect complementarity of at least 19 nucleotides wherein the antisense strand of the second interfering RNA hybridizes under physiological conditions to a portion of mRNA corresponding to SEQ ID NO:1 comprising a nucleotide as cited above, or where the antisense strand hybridizes under physiological conditions to a portion of mRNA corresponding to SEQ ID NO:2 beginning at nucleotide 124, 328, 387, 391, 393, 395, 406, 421, 423, 444, 447, 455, 459, 460, 467, 469, 470, 471, 475, 479, 513, 517, 531, 543, 556, 576, 587, 588, 589, 595, 601, 602, 611, 612, 651, 664, 667, 668, 669, 677, 678, 785, 786, 788, 791, 792, 804, 813, 824, 838, 843, 877, 884, 929, 959, 960, 961, 963, 964, 965, 970, 973, 974, 1000, 1002, 1013, 1026, 1053, 1056, 1057, 1058, 1161, 1315, 1318, 1324, 1357, 1360, 1383, 1393, 1420, 1471, 1573, 1671, 2044, 2045, 2046, 2047, 2048, 2089, 2090, 2091, 2092, or 2098.

[0016] When a first interfering RNA targets SEQ ID NO:1, the second interfering RNA may target either SEQ ID NO:1 or SEQ ID NO:2, and conversely, when a first interfering RNA targets SEQ ID NO:2, the second interfering RNA may target either SEQ ID NO:1 or SEQ ID NO:2. In further embodiments, a third, fourth, or more interfering RNAs may be administered.

[0017] A further embodiment of the invention is a method of treating a TNF.alpha.-related condition in a subject in need thereof, where the method comprises administering to the subject a composition comprising a double stranded siRNA molecule that down regulates expression of a TACE gene via RNA interference, wherein each strand of the siRNA molecule is independently about 19 to about 27 nucleotides in length; and one strand of the siRNA molecule comprises a nucleotide sequence having substantial complementarity to an mRNA corresponding to the TACE gene, so that the siRNA molecule directs cleavage of the mRNA via RNA interference.

[0018] A further embodiment of the invention is a method of treating a TNF.alpha.-related ocular condition in a subject in need thereof, where the method comprises administering to the subject a composition comprising a double stranded siRNA molecule that down regulates expression of a TNFR1 gene via RNA interference, wherein each strand of the siRNA molecule is independently about 19 to about 27 nucleotides in length; and one strand of the siRNA molecule comprises a nucleotide sequence having substantial complementarity to an mRNA corresponding to the TNFR1 gene so that the siRNA molecule directs cleavage of the mRNA via RNA interference.

[0019] A method of attenuating expression of TACE mRNA of the subject, comprising administering to the subject a composition comprising an effective amount of a single-stranded interfering RNA and a pharmaceutically acceptable carrier is a further embodiment. The single-stranded interfering RNA has a length of 19 to 49 nucleotides and hybridizes under physiological conditions to a portion of mRNA corresponding to SEQ ID NO:1 comprising nucleotide 297, 333, 334, 335, 434, 470, 493, 547, 570, 573, 618, 649, 689, 755, 842, 844, 846, 860, 878, 894, 900, 909, 910, 913, 942, 970, 984, 1002, 1010, 1053, 1064, 1137, 1162, 1215, 1330, 1334, 1340, 1386, 1393, 1428, 1505, 1508, 1541, 1553, 1557, 1591, 1592, 1593, 1597, 1604, 1605, 1626, 1632, 1658, 1661, 1691, 1794, 1856, 1945, 1946, 1947, 1958, 2022, 2094, 2100, 2121, 2263, 2277, 2347, 2349, 2549, 2578, 2595, 2606, 2608, 2629, 2639, 2764, 2766, 2767, 2769, 3027, 3028, 3261, 3264, 3284, 3313, 3317, 3332, or 3337, and the interfering RNA has a region of at least near-perfect contiguous complementarity with the hybridizing portion of mRNA corresponding to SEQ ID NO:1. The expression of TACE mRNA is thereby attenuated.

[0020] The invention includes as a further embodiment a composition comprising an interfering RNA having a length of 19 to 49 nucleotides, and comprising a nucleotide sequence corresponding to any one of SEQ ID NO:3, SEQ ID NO:14-SEQ ID NO:58, and SEQ ID NO:155-SEQ ID NO:201, or a complement thereof; and a pharmaceutically acceptable carrier.

[0021] The invention includes as a further embodiment a composition comprising an interfering RNA consisting essentially of a nucleotide sequence corresponding to any one of SEQ ID NO:59-SEQ ID NO:69, SEQ ID NO:71-SEQ ID NO:92, and SEQ ID NO:94-SEQ ID NO:154, or a complement thereof; and a pharmaceutically acceptable carrier.

[0022] Use of any of the embodiments as described herein in the preparation of a medicament for attenuating expression of TACE mRNA or of TNFR1 mRNA as a method of attenuating activity of TNF.alpha. and thereby treating a TNF.alpha.-related condition as set forth herein is also an embodiment of the present invention.

BRIEF DESCRIPTION OF THE FIGURES

[0023] In order that the manner in which the above recited and other advantages and objects of the invention are obtained, a more particular description of the invention briefly described above will be rendered by reference to specific embodiments thereof, which are illustrated, in the appended drawings. Understanding that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope, the invention will be described with additional specificity and detail through the use of the accompanying drawings in which:

[0024] FIG. 1 provides a TNFR1 western blot of GTM-3 cells transfected with TNFR1 siRNAs #1, #2, #3, and #4, and a RISC-free control siRNA, each at 10 nM, 1 nM, and 0.1 nM; a non-targeting control siRNA (NTC2) at 10 nM; and a buffer control (-siRNA). The arrows indicate the positions of the 55-kDa TNFR1 and 42-kDa actin bands.

DETAILED DESCRIPTION OF THE INVENTION

[0025] The references cited herein, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated by reference.

[0026] Those of skill in the art, in light of the present disclosure, will appreciate that obvious modifications of the embodiments disclosed herein can be made without departing from the spirit and scope of the invention. All of the embodiments disclosed herein can be made and executed without undue experimentation in light of the present disclosure. The full scope of the invention is set out in the disclosure and equivalent embodiments thereof The specification should not be construed to unduly narrow the full scope of protection to which the present invention is entitled.

[0027] The particulars shown herein are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of various embodiments of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for the fundamental understanding of the invention, the description taken with the drawings and/or examples making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.

[0028] The following definitions and explanations are meant and intended to be controlling in any future construction unless clearly and unambiguously modified in the following examples or when application of the meaning renders any construction meaningless or essentially meaningless. In cases where the construction of the term would render it meaningless or essentially meaningless, the definition should be taken from Webster's Dictionary, 3rd Edition.

[0029] As used herein, all percentages are percentages by weight, unless stated otherwise.

[0030] As used herein and unless otherwise indicated, the terms "a" and "an" are taken to mean "one", "at least one" or "one or more".

[0031] The term "dry eye," also known as conjunctivitis sicca or keratoconjunctivitis sicca, is a common ophthalmological disorder involving breakdown of the pre-ocular tear film, resulting in dehydration of the exposed outer surface of the eye.

[0032] The term "ocular inflammation," as used herein, includes iritis, uveitis, episcleritis, scleritis, keratitis, endophthalmitis, blepharitis, and iatrogenic inflammatory conditions, for example.

[0033] The term "allergic conjunctivitis," as used herein, refers to inflammation of the conjunctiva which is the delicate membrane that lines the eyelids and covers the exposed surface of the sclera. The term "allergic conjunctivitis" includes, for example, atopic keratoconjunctivitis, giant papillary conjunctivitis, hay fever conjunctivitis, perennial allergic conjunctivitis, and vernal keratoconjunctivitis.

[0034] The term "dermatitis," as used herein, refers to inflammation of the skin and includes, for example, allergic contact dermatitis, urticaria, asteatotic dermatitis (dry skin on the lower legs), atopic dermatitis, contact dermatitis including irritant contact dermatitis and urushiol-induced contact dermatitis, eczema, gravitational dermatitis, nummular dermatitis, otitis externa, perioral dermatitis, and seborrhoeic dermatitis.

[0035] The term "rhinitis," as used herein, refers to inflammation of the mucous membranes of the nose and includes, for example, allergic rhinitis, atopic rhinitis, irritant rhinitis, eosinophilic non-allergic rhinitis, rhinitis medicamentosa, and neutrophilic rhinosinusitis.

[0036] The term "asthma," as used herein, refers to inflammation of the air passages resulting in narrowing of the airways that transport air from the nose and mouth to the lungs and includes, for example, allergic asthma, atopic asthma, atopic bronchial IgE-mediated asthma, bronchial asthma, bronchiolytis, emphysematous asthma, essential asthma, exercise-induced asthma, extrinsic asthma caused by environmental factors, incipient asthma, intrinsic asthma caused by pathophysiologic disturbances, non-allergic asthma, non-atopic asthma, and wheezy infant syndrome.

[0037] The phrase "a region of at least 13 contiguous nucleotides having at least 90% sequence complementarity to, or at least 90% sequence identity with, the penultimate 13 nucleotides of the 3' end of an mRNA corresponding to any one of (a sequence identifier)" allows a one nucleotide substitution. Two nucleotide substitutions (i.e., 11/13=85% identity/complementarity) are not included in such a phrase.

[0038] The term "percent identity" describes the percentage of contiguous nucleotides in a first nucleic acid molecule that is the same as in a set of contiguous nucleotides of the same length in a second nucleic acid molecule. The term "percent complementarity" describes the percentage of contiguous nucleotides in a first nucleic acid molecule that can base pair in the Watson-Crick sense with a set of contiguous nucleotides in a second nucleic acid molecule.

[0039] As used herein, the term "hybridization" means and refers to a process in which single-stranded nucleic acids with complementary or near-complementary base sequences interact to form hydrogen-bonded complexes called hybrids. Hybridization reactions are sensitive and selective. In vitro, the specificity of hybridization (i.e., stringency) is controlled by the concentrations of salt or formamide in prehybridization and hybridization solutions, for example, and by the hybridization temperature; such procedures are well known in the art. In particular, stringency is increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

[0040] For example, high stringency conditions could occur at about 50% formamide at 37.degree. C. to 42.degree. C. Reduced stringency conditions could occur at about 35% to 25% formamide at 30.degree. C. to 35.degree. C. Examples of stringency conditions for hybridization are provided in Sambrook, J., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Further examples of stringent hybridization conditions include 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50.degree. C. or 70.degree. C. for 12-16 hours followed by washing, or hybridization at 70.degree. C. in 1.times.SSC or 50.degree. C. in 1.times.SSC, 50% formamide followed by washing at 70.degree. C. in 0.3.times.SSC, or hybridization at 70.degree. C. in 4.times.SSC or 50.degree. C. in 4.times.SSC, 50% formamide followed by washing at 67.degree. C. in 1.times.SSC. The temperature for hybridization is about 5-10.degree. C. less than the melting temperature (T.sub.m) of the hybrid where T.sub.m is determined for hybrids between 19 and 49 base pairs in length using the following calculation: T.sub.m.degree. C.=81.5+16.6(log.sub.10 [Na+])+0.41 (% G+C)-(600/N) where N is the number of bases in the hybrid, and [Na+] is the concentration of sodium ions in the hybridization buffer.

[0041] Nucleic acid sequences cited herein are written in a 5' to 3' direction unless indicated otherwise. The term "nucleic acid," as used herein, refers to either DNA or RNA or a modified form thereof comprising the purine or pyrimidine bases present in DNA (adenine "A," cytosine "C," guanine "G," thymine "T") or in RNA (adenine "A," cytosine "C," guanine "G," uracil "U"). Interfering RNAs provided herein may comprise "T" bases, particularly at 3' ends, even though "T" bases do not naturally occur in RNA. "Nucleic acid" includes the terms "oligonucleotide" and "polynucleotide" and can refer to a single-stranded molecule or a double-stranded molecule. A double-stranded molecule is formed by Watson-Crick base pairing between A and T bases, C and G bases, and between A and U bases. The strands of a double-stranded molecule may have partial, substantial or full complementarity to each other and will form a duplex hybrid, the strength of bonding of which is dependent upon the nature and degree of complementarity of the sequence of bases.

[0042] An mRNA sequence is readily deduced from the sequence of the corresponding DNA sequence. For example, SEQ ID NO:1 provides the sense strand sequence of DNA corresponding to the mRNA for TACE. The mRNA sequence is identical to the DNA sense strand sequence with the "T" bases replaced with "U" bases. Therefore, the mRNA sequence of TACE is known from SEQ ID NO:1 and the mRNA of TNFR1 is known from SEQ ID NO:2.

[0043] RNA interference (RNAi) is a process by which double-stranded RNA (dsRNA) is used to silence gene expression. While not wanting to be bound by theory, RNAi begins with the cleavage of longer dsRNAs into small interfering RNAs (siRNAs) by an RNaseIII-like enzyme, dicer. SiRNAs are dsRNAs that are usually about 19 to 28 nucleotides, or 20 to 25 nucleotides, or 21 to 22 nucleotides in length and often contain 2-nucleotide 3' overhangs, and 5' phosphate and 3' hydroxyl termini. One strand of the siRNA is incorporated into a ribonucleoprotein complex known as the RNA-induced silencing complex (RISC). RISC uses this siRNA strand to identify mRNA molecules that are at least partially complementary to the incorporated siRNA strand, and then cleaves these target mRNAs or inhibits their translation. Therefore, the siRNA strand that is incorporated into RISC is known as the guide strand or the antisense strand. The other siRNA strand, known as the passenger strand or the sense strand, is eliminated from the siRNA and is at least partially homologous to the target mRNA. Those of skill in the art will recognize that, in principle, either strand of an siRNA can be incorporated into RISC and function as a guide strand. However, siRNA design (e.g., decreased siRNA duplex stability at the 5' end of the antisense strand) can favor incorporation of the antisense strand into RISC.

[0044] RISC-mediated cleavage of mRNAs having a sequence at least partially complementary to the guide strand leads to a decrease in the steady state level of that mRNA and of the corresponding protein encoded by this mRNA. Alternatively, RISC can also decrease expression of the corresponding protein via translational repression without cleavage of the target mRNA. Other RNA molecules and RNA-like molecules can also interact with RISC and silence gene expression. Examples of other RNA molecules that can interact with RISC include short hairpin RNAs (shRNAs), single-stranded siRNAs, microRNAs (miRNAs), and dicer-substrate 27-mer duplexes. The term "siRNA" as used herein refers to a double-stranded interfering RNA unless otherwise noted. Examples of RNA-like molecules that can interact with RISC include RNA molecules containing one or more chemically modified nucleotides, one or more deoxyribonucleotides, and/or one or more non-phosphodiester linkages. For purposes of the present discussion, all RNA or RNA-like molecules that can interact with RISC and participate in RISC-mediated changes in gene expression will be referred to as "interfering RNAs." SiRNAs, shRNAs, miRNAs, and dicer-substrate 27-mer duplexes are, therefore, subsets of "interfering RNAs."

[0045] Interfering RNA of embodiments of the invention appear to act in a catalytic manner for cleavage of target mRNA, i.e., interfering RNA is able to effect inhibition of target mRNA in substoichiometric amounts. As compared to antisense therapies, significantly less interfering RNA is required to provide a therapeutic effect under such cleavage conditions.

[0046] The present invention relates to the use of interfering RNA to inhibit the expression of TNF.alpha. cell surface receptor TNF receptor-1 (TNFR1), or the TNF.alpha. converting enzyme (TACE/ADAM17, designated herein "TACE") which inhibition effects reduction of tumor necrosis factor .alpha. (TNF.alpha.) activity. Binding of TNF.alpha. to its cell surface receptor, TNF receptor-1 (TNFR1), activates a signaling cascade which affects a variety of cellular responses including apoptosis and inflammation. TNF.alpha. itself is initially expressed as an inactive, membrane-bound precursor. Release of the active form of TNF.alpha. from the cell surface requires proteolytic processing of the precursor by TNF.alpha. converting enzyme (TACE/ADAM17), a member of the `A Disintegrin And Metalloprotease` (ADAM) family.

[0047] According to the present invention, inhibiting the expression of TNFR1 mRNA, TACE mRNA, or both TNFR1 and TACE mRNAs effectively reduces the action of TNF.alpha.. Further, interfering RNAs as set forth herein provided exogenously or expressed endogenously are particularly effective at silencing TNFR1 mRNA or TACE mRNA.

[0048] Tumor Necrosis Factor a Converting Enzyme mRNA (TACE/ADAM17): The GenBank database provides the DNA sequence for TACE as accession no. NM_003183, provided in the "Sequence Listing" as SEQ ID NO:1. SEQ ID NO:1 provides the sense strand sequence of DNA that corresponds to the mRNA encoding TACE (with the exception of "T" bases for "U" bases). The coding sequence for TACE is from nucleotides 184-2658.

[0049] Equivalents of the above cited TACE mRNA sequence are alternative splice forms, allelic forms, isozymes, or a cognate thereof. A cognate is a tumor necrosis factor a converting enzyme mRNA from another mammalian species that is homologous to SEQ ID NO:1 (i.e., an ortholog).

[0050] Tumor Necrosis Factor Receptor-1 mRNA (TNFR1): The GenBank database provides the DNA sequence for TNFR1 as accession no. NM_001065, provided in the "Sequence Listing" as SEQ ID NO:2. SEQ ID NO:2 provides the sense strand sequence of DNA that corresponds to the mRNA encoding TNFR1 (with the exception of "T" bases for "U" bases). The coding sequence for TNFR1 is from nucleotides 282-1649.

[0051] Equivalents of the above cited TNFR1 mRNA sequence are alternative splice forms, allelic forms, isozymes, or a cognate thereof. A cognate is a tumor necrosis factor receptor-1 mRNA from another mammalian species that is homologous to SEQ ID NO:2 (i.e., an ortholog).

[0052] Attenuating expression of an mRNA: The phrase, "attenuating expression of an mRNA," as used herein, means administering or expressing an amount of interfering RNA (e.g., an siRNA) to reduce translation of the target mRNA into protein, either through mRNA cleavage or through direct inhibition of translation. The reduction in expression of the target mRNA or the corresponding protein is commonly referred to as "knock-down" and is reported relative to levels present following administration or expression of a non-targeting control RNA (e.g., a non-targeting control siRNA). Knock-down of expression of an amount including and between 50% and 100% is contemplated by embodiments herein. However, it is not necessary that such knock-down levels be achieved for purposes of the present invention. In one embodiment, a single interfering RNA targeting TACE mRNA or TNFR1 mRNA is administered. In other embodiments, two or more interfering RNAs targeting TACE mRNA or TNFR1 mRNA are administered. In further embodiments, interfering RNAs targeting each of TACE mRNA and TNFR1 mRNA are administered in combination or in a time interval so as to have overlapping effects.

[0053] Knock-down is commonly assessed by measuring the mRNA levels using quantitative polymerase chain reaction (qPCR) amplification or by measuring protein levels by western blot or enzyme-linked immunosorbent assay (ELISA). Analyzing the protein level provides an assessment of both mRNA cleavage as well as translation inhibition. Further techniques for measuring knock-down include RNA solution hybridization, nuclease protection, northern hybridization, gene expression monitoring with a microarray, antibody binding, radioimmunoassay, and fluorescence activated cell analysis.

[0054] Inhibition of TACE or TNFR1 may also be determined in vitro by evaluating target mRNA levels or target protein levels in, for example, human corneal epithelial cells following transfection of TACE- or TNFR1-interfering RNA as described infra.

[0055] Inhibition of TNF.alpha. activity due to inhibition of TACE mRNA expression or of TNFR1 mRNA expression is also inferred in a human or mammal by observing an improvement in a TNF.alpha.-related condition symptom such as improvement in symptoms related to dry eye, allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, or asthma. Improvement in any of dry eye symptoms, edema, itching, inflammation, or tolerance to environmental challenges, for example, is indicative of inhibition of TNF.alpha. activity.

[0056] Interfering RNA: In one embodiment of the invention, interfering RNA (e.g., siRNA) has a sense strand and an antisense strand, and the sense and antisense strands comprise a region of at least near-perfect contiguous complementarity of at least 19 nucleotides. In a further embodiment of the invention, interfering RNA (e.g., siRNA) has a sense strand and an antisense strand, and the antisense strand comprises a region of at least near-perfect contiguous complementarity of at least 19 nucleotides to a target sequence of TACE mRNA or TNFR1 mRNA, and the sense strand comprises a region of at least near-perfect contiguous identity of at least 19 nucleotides with a target sequence of TACE mRNA or TNFR1 mRNA, respectively. In a further embodiment of the invention, the interfering RNA comprises a region of at least 13, 14, 15, 16, 17, or 18 contiguous nucleotides having percentages of sequence complementarity to or, having percentages of sequence identity with, the penultimate 13, 14, 15, 16, 17, or 18 nucleotides, respectively, of the 3' end of the corresponding target sequence within an mRNA.

[0057] The length of each strand of the interfering RNA comprises 19 to 49 nucleotides, and may comprise a length of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or 49 nucleotides.

[0058] The antisense strand of an siRNA is the active guiding agent of the siRNA in that the antisense strand is incorporated into RISC, thus allowing RISC to identify target mRNAs with at least partial complementarity to the antisense siRNA strand for cleavage or translational repression.

[0059] In embodiments of the present invention, interfering RNA target sequences (e.g., siRNA target sequences) within a target mRNA sequence are selected using available design tools. Interfering RNAs corresponding to a TACE or TNFR1 target sequence are then tested by transfection of cells expressing the target mRNA followed by assessment of knockdown as described above.

[0060] Techniques for selecting target sequences for siRNAs are provided by Tuschl, T. et al., "The siRNA User Guide," revised May 6, 2004, available on the Rockefeller University web site; by Technical Bulletin #506, "siRNA Design Guidelines," Ambion Inc. at Ambion's web site; and by other web-based design tools at, for example, the Invitrogen, Dharmacon, Integrated DNA Technologies, Genscript, or Proligo web sites. Initial search parameters can include G/C contents between 35% and 55% and siRNA lengths between 19 and 27 nucleotides. The target sequence may be located in the coding region or in the 5' or 3' untranslated regions of the mRNAs.

[0061] An embodiment of a 19-nucleotide DNA target sequence for TACE mRNA is present at nucleotides 297 to 315 of SEQ ID NO:1:

TABLE-US-00001 5'- GCTCTCAGACTACGATATT -3'. SEQ ID NO: 3

An siRNA of the invention for targeting a corresponding mRNA sequence of SEQ ID NO:3 and having 21-nucleotide strands and a 2-nucleotide 3' overhang is:

TABLE-US-00002 5'- GCUCUCAGACUACGAUAUUNN -3' SEQ ID NO: 4 3'- NNCGAGAGUCUGAUGCUAUAA -5'. SEQ ID NO: 5

Each "N" residue can be any nucleotide (A, C, G, U, T) or modified nucleotide. The 3' end can have a number of "N" residues between and including 1, 2, 3, 4, 5, and 6. The "N" residues on either strand can be the same residue (e.g., UU, AA, CC, GG, or TT) or they can be different (e.g., AC, AG, AU, CA, CG, CU, GA, GC, GU, UA, UC, or UG). The 3' overhangs can be the same or they can be different. In one embodiment, both strands have a 3'UU overhang.

[0062] An siRNA of the invention for targeting a corresponding mRNA sequence of SEQ ID NO:3 and having 21-nucleotide strands and a 3'UU overhang on each strand is:

TABLE-US-00003 5'- GCUCUCAGACUACGAUAUUUU -3' SEQ ID NO: 6 3'- UUCGAGAGUCUGAUGCUAUAA -5'. SEQ ID NO: 7

[0063] The interfering RNA may also have a 5' overhang of nucleotides or it may have blunt ends. An siRNA of the invention for targeting a corresponding mRNA sequence of SEQ ID NO:3 and having 19-nucleotide strands and blunt ends is:

TABLE-US-00004 5'- GCUCUCAGACUACGAUAUU -3' SEQ ID NO: 8 3'- CGAGAGUCUGAUGCUAUAA -5'. SEQ ID NO: 9

[0064] The strands of a double-stranded interfering RNA (e.g., an siRNA) may be connected to form a hairpin or stem-loop structure (e.g., an shRNA). An shRNA of the invention targeting a corresponding mRNA sequence of SEQ ID NO:3 and having a 19 bp double-stranded stem region and a 3'UU overhang is:

##STR00001##

N is a nucleotide A, T, C, G, U, or a modified form known by one of ordinary skill in the art. The number of nucleotides N in the loop is a number between and including 3 to 23, or 5 to 15, or 7 to 13, or 4 to 9, or 9 to 11, or the number of nucleotides N is 9. Some of the nucleotides in the loop can be involved in base-pair interactions with other nucleotides in the loop. Examples of oligonucleotide sequences that can be used to form the loop include 5'-UUCAAGAGA-3' (Brummelkamp, T. R. et al. (2002) Science 296: 550) and 5'-UUUGUGUAG-3' (Castanotto, D. et al. (2002) RNA 8:1454). It will be recognized by one of skill in the art that the resulting single chain oligonucleotide forms a stem-loop or hairpin structure comprising a double-stranded region capable of interacting with the RNAi machinery.

[0065] The siRNA target sequence identified above can be extended at the 3' end to facilitate the design of dicer-substrate 27-mer duplexes. Extension of the 19-nucleotide DNA target sequence (SEQ ID NO:3) identified in the TACE DNA sequence (SEQ ID NO:1) by 6 nucleotides yields a 25-nucleotide DNA target sequence present at nucleotides 297 to 321 of SEQ ID NO:1:

TABLE-US-00005 5'- GCTCTCAGACTACGATATTCTCTCT -3'. SEQ ID NO: 11

A dicer-substrate 27-mer duplex of the invention for targeting a corresponding mRNA sequence of SEQ ID NO:11 is:

TABLE-US-00006 5'- GCUCUCAGACUACGAUAUUCUCUCU -3' SEQ ID NO: 12 3'- UUCGAGAGUCUGAUGCUAUAAGAGAGA -5'. SEQ ID NO: 13

The two nucleotides at the 3' end of the sense strand (i.e., the CU nucleotides of SEQ ID NO:12) may be deoxynucleotides for enhanced processing. Design of dicer-substrate 27-mer duplexes from 19-21 nucleotide target sequences, such as provided herein, is further discussed by the Integrated DNA Technologies (IDT) website and by Kim, D.-H. et al., (February, 2005) Nature Biotechnology 23:2; 222-226.

[0066] When interfering RNAs are produced by chemical synthesis, phosphorylation at the 5' position of the nucleotide at the 5' end of one or both strands (when present) can enhance siRNA efficacy and specificity of the bound RISC complex but is not required since phosphorylation can occur intracellularly.

[0067] Table 1 lists examples of TACE DNA target sequences of SEQ ID NO:1 from which siRNAs of the present invention are designed in a manner as set forth above. TACE encodes tumor necrosis factor .alpha. converting enzyme, as noted above.

TABLE-US-00007 TABLE 1 TACE Target Sequences for siRNAs # of Starting Nucleotide with SEQ TACE reference to ID Target Sequence SEQ ID NO: 1 NO: GCTCTCAGACTACGATATT 297 3 CCAGCAGCATTCGGTAAGA 333 14 CAGCAGCATTCGGTAAGAA 334 15 AGCAGCATTCGGTAAGAAA 335 16 AGAGATCTACAGACTTCAA 355 17 GAAAGCGAGTACACTGTAA 493 18 CCATGAAGAACACGTGTAA 842 19 GAAGAACACGTGTAAATTA 846 20 ATCATCGCTTCTACAGATA 878 21 AGAGCAATTTAGCTTTGAT 1137 22 GGTTTGACGAGCACAAAGA 1330 23 TGATCCGGATGGTCTAGCA 1428 24 GCGATCACGAGAACAATAA 1508 25 GCAGTAAACAATCAATCTA 1541 26 CAATCTATAAGACCATTGA 1553 27 TTTCAAGAACGCAGCAATA 1591 28 TTCAAGAACGCAGCAATAA 1592 29 TCAAGAACGCAGCAATAAA 1593 30 TCATGTATCTGAACAACGA 1661 31 ACAGCGACTGCACGTTGAA 1691 32 GATTAATGCTACTTGCAAA 1794 33 CTGGAGTCCTGTGCATGTA 1945 34 TGGAGTCCTGTGCATGTAA 1946 35 GGAGTCCTGTGCATGTAAT 1947 36 CATGTAATGAAACTGACAA 1958 37 CTATGTCGATGCTGAACAA 2022 38 CAAATGTGAGAAACGAGTA 2100 39 GCATCGGTTCGCATTATCA 2347 40 ATCGGTTCGCATTATCAAA 2349 41 CCAAGTCATTTGAGGATCT 2549 42 CCGGTCACCAGAAGTGAAA 2578 43 AAAGGCTGCCTCCTTTAAA 2595 44 TTTAAACTGCAGCGTCAGA 2608 45 AGATGCTGGTCATGTGTTT 2764 46 ATGCTGGTCATGTGTTTGA 2766 47 TGCTGGTCATGTGTTTGAA 2767 48 CTGGTCATGTGTTTGAACT 2769 49 TGTAATGAACCGCTGAATA 3027 50 GTAATGAACCGCTGAATAT 3028 51 CTAAGACTAATGCTCTCTA 3261 52 AGACTAATGCTCTCTAGAA 3264 53 CCTAACCACCTACCTTACA 3284 54 TACATGGTAGCCAGTTGAA 3313 55 TGGTAGCCAGTTGAATTTA 3317 56 TTTATGGAATCTACCAACT 3332 57 GGAATCTACCAACTGTTTA 3337 58 CATCAAGTACTGAACGTTT 434 155 TCGTGGTGGTGGATGGTAA 470 156 GAAAGCGAGTACACTGTAA 493 157 GAGCCTGACTCTAGGGTTC 547 158 CCACATAAGAGATGATGAT 570 159 CATAAGAGATGATGATGTT 573 160 CGAATATAACATAGAGCCA 618 161 GTTAATGATACCAAAGACA 649 162 CTGAAGATATCAAGAATGT 689 163 ATGAAGAGTTGCTCCCAAA 755 164 ATGAAGAACACGTGTAAAT 844 165 AATTATTGGTGGTAGCAGA 860 166 ATCATCGCTTCTACAGATA 878 167 ATACATGGGCAGAGGGGAA 894 168 GGGCAGAGGGGAAGAGAGT 900 169 GGAAGAGAGTACAACTACA 909 170 GAAGAGAGTACAACTACAA 910 171 GAGAGTACAACTACAAATT 913 172 GCTAATTGACAGAGTTGAT 942 173 CGGAACACTTCATGGGATA 970 174 GGATAATGCAGGTTTTAAA 984 175 AGGCTATGGAATACAGATA 1002 176 GAATACAGATAGAGCAGAT 1010 177 GGTAAAACCTGGTGAAAAG 1053 178 GTGAAAAGCACTACAACAT 1064 179 GAGGAAGCATCTAAAGTTT 1162 180 TATGGGAACTCTTGGATTA 1215 181 TGACGAGCACAAAGAATTA 1334 182 GCACAAAGAATTATGGTAA 1340 183 GGTTACAACTCATGAATTG 1386 184 ACTCATGAATTGGGACATA 1393 185 GTGGCGATCACGAGAACAA 1505 186 CTATAAGACCATTGAAAGT 1557 187 GAACGCAGCAATAAAGTTT 1597 188 GCAATAAAGTTTGTGGGAA 1604 189 CAATAAAGTTTGTGGGAAC 1605 190 GAGGGTGGATGAAGGAGAA 1626 191 GGATGAAGGAGAAGAGTGT 1632 192 GCATCATGTATCTGAACAA 1658 193 CAGGAAATGCTGAAGATGA 1856 194 GAATGGCAAATGTGAGAAA 2094 195 GGATGTAATTGAACGATTT 2121 196 GTGGATAAGAAATTGGATA 2263 197 GGATAAACAGTATGAATCT 2277 198 CCTTTAAACTGCAGCGTCA 2606 199 CGTGTTGACAGCAAAGAAA 2629 200 GCAAAGAAACAGAGTGCTA 2639 201

Table 2 lists examples of TNFR1 DNA target sequences of SEQ ID NO:2 from which siRNAs of the present invention are designed in a manner as set forth above. TNFR1 encodes tumor necrosis factor .alpha. receptor-1, as noted above.

TABLE-US-00008 TABLE 2 TNFR1 Target Sequences for siRNAs # of Starting Nucleotide with SEQ TNFR1 reference to ID Target Sequence SEQ ID NO: 2 NO: ACCAGGCCGTGATCTCTAT 124 59 AATTCGATTTGCTGTACCA 444 60 TCGATTTGCTGTACCAAGT 447 61 ACAAAGGAACCTACTTGTA 469 62 GAACCTACTTGTACAATGA 475 63 CTACTTGTACAATGACTGT 479 64 TGTGAGAGCGGCTCCTTCA 531 65 TCAGGTGGAGATCTCTTCT 611 66 CAGGTGGAGATCTCTTCTT 612 67 AGAACCAGTACCGGCATTA 667 68 GAACCAGTACCGGCATTAT 668 69 AACCAGTACCGGCATTATT 669 70 CCGGCATTATTGGAGTGAA 677 71 CGGCATTATTGGAGTGAAA 678 72 AGCCTGGAGTGCACGAAGT 843 73 CTCCTCTTCATTGGTTTAA 960 74 TTGGTTTAATGTATCGCTA 970 75 GTTTAATGTATCGCTACCA 973 76 TTTAATGTATCGCTACCAA 974 77 AGTCCAAGCTCTACTCCAT 1000 78 GAGCTTGAAGGAACTACTA 1053 79 CTTGAAGGAACTACTACTA 1056 80 TTGAAGGAACTACTACTAA 1057 81 ACAAGCCACAGAGCCTAGA 1318 82 TGTACGCCGTGGTGGAGAA 1357 83 CCGTTGCGCTGGAAGGAAT 1383 84 TCTAAGGACCGTCCTGCGA 1671 85 CTAATAGAAACTTGGCACT 2044 86 TAATAGAAACTTGGCACTC 2045 87 AATAGAAACTTGGCACTCC 2046 88 ATAGAAACTTGGCACTCCT 2047 89 TAGAAACTTGGCACTCCTG 2048 90 ATAGCAAGCTGAACTGTCC 2089 91 TAGCAAGCTGAACTGTCCT 2090 92 AGCAAGCTGAACTGTCCTA 2091 93 GCAAGCTGAACTGTCCTAA 2092 94 TGAACTGTCCTAAGGCAGG 2098 95 CAAAGGAACCTACTTGTAC 470 96 GAGCTTGAAGGAACTACTA 1053 97 CACAGAGCCTAGACACTGA 1324 98 TCCAAGCTCTACTCCATTG 1002 99 TGGAGCTGTTGGTGGGAAT 328 100 GACAGGGAGAAGAGAGATA 387 101 GGGAGAAGAGAGATAGTGT 391 102 GAGAAGAGAGATAGTGTGT 393 103 GAAGAGAGATAGTGTGTGT 395 104 GTGTGTGTCCCCAAGGAAA 406 105 GAAAATATATCCACCCTCA 421 106 AAATATATCCACCCTCAAA 423 107 CTGTACCAAGTGCCACAAA 455 108 ACCAAGTGCCACAAAGGAA 459 109 CCAAGTGCCACAAAGGAAC 460 110 CCACAAAGGAACCTACTTG 467 111 CAAAGGAACCTACTTGTAC 470 112 AAAGGAACCTACTTGTACA 471 113 GATACGGACTGCAGGGAGT 513 114 CGGACTGCAGGGAGTGTGA 517 115 TCCTTCACCGCTTCAGAAA 543 116 CAGAAAACCACCTCAGACA 556 117 TGCCTCAGCTGCTCCAAAT 576 118 CTCCAAATGCCGAAAGGAA 587 119 TCCAAATGCCGAAAGGAAA 588 120 CCAAATGCCGAAAGGAAAT 589 121 GCCGAAAGGAAATGGGTCA 595 122 AGGAAATGGGTCAGGTGGA 601 123 GGAAATGGGTCAGGTGGAG 602 124 GTGTGTGGCTGCAGGAAGA 651 125 GGAAGAACCAGTACCGGCA 664 126 CCATGCAGGTTTCTTTCTA 785 127 CATGCAGGTTTCTTTCTAA 786 128 TGCAGGTTTCTTTCTAAGA 788 129 AGGTTTCTTTCTAAGAGAA 791 130 GGTTTCTTTCTAAGAGAAA 792 131 AGAGAAAACGAGTGTGTCT 804 132 GAGTGTGTCTCCTGTAGTA 813 133 CTGTAGTAACTGTAAGAAA 824 134 AGAAAAGCCTGGAGTGCAC 838 135 TTGAGAATGTTAAGGGCAC 877 136 TGTTAAGGGCACTGAGGAC 884 137 GGTCATTTTCTTTGGTCTT 929 138 CCTCCTCTTCATTGGTTTA 959 139 TCCTCTTCATTGGTTTAAT 961 140 CTCTTCATTGGTTTAATGT 963 141 TCTTCATTGGTTTAATGTA 964 142 CTTCATTGGTTTAATGTAT 965 143 TCCAAGCTCTACTCCATTG 1002 144 CTCCATTGTTTGTGGGAAA 1013 145 GGGAAATCGACACCTGAAA 1026 146 TGAAGGAACTACTACTAAG 1058 147 ACCTCCAGCTCCACCTATA 1161 148 CCCACAAGCCACAGAGCCT 1315 149 ACGCCGTGGTGGAGAACGT 1360 150 GGAAGGAATTCGTGCGGCG 1393 151 TGAGCGACCACGAGATCGA 1420 152 GCGAGGCGCAATACAGCAT 1471 153 TGGGCTGCCTGGAGGACAT 1573 154

[0068] As cited in the examples above, one of skill in the art is able to use the target sequence information provided in Tables 1 or 2 to design interfering RNAs having a length shorter or longer than the sequences provided in the tables and by referring to the sequence position in SEQ ID NO:1 or SEQ ID NO:2 and adding or deleting nucleotides complementary or near complementary to SEQ ID NO:1 or SEQ ID NO:2, respectively.

[0069] The target RNA cleavage reaction guided by siRNAs and other forms of interfering RNA is highly sequence specific. In general, siRNA containing a sense nucleotide strand identical in sequence to a portion of the target mRNA and an antisense nucleotide strand exactly complementary to a portion of the target mRNA are siRNA embodiments for inhibition of mRNAs cited herein. However, 100% sequence complementarity between the antisense siRNA strand and the target mRNA, or between the antisense siRNA strand and the sense siRNA strand, is not required to practice the present invention. Thus, for example, the invention allows for sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence.

[0070] In one embodiment of the invention, the antisense strand of the siRNA has at least near-perfect contiguous complementarity of at least 19 nucleotides with the target mRNA. "Near-perfect," as used herein, means the antisense strand of the siRNA is "substantially complementary to," and the sense strand of the siRNA is "substantially identical" to at least a portion of the target mRNA. "Identity," as known by one of ordinary skill in the art, is the degree of sequence relatedness between nucleotide sequences as determined by matching the order and identity of nucleotides between the sequences. In one embodiment, the antisense strand of an siRNA having 80% and between 80% up to 100% complementarity, for example, 85%, 90% or 95% complementarity, to the target mRNA sequence are considered near-perfect complementarity and may be used in the present invention. "Perfect" contiguous complementarity is standard Watson-Crick base pairing of adjacent base pairs. "At least near-perfect" contiguous complementarity includes "perfect" complementarity as used herein. Computer methods for determining identity or complementarity are designed to identify the greatest degree of matching of nucleotide sequences, for example, BLASTN (Altschul, S. F., et al. (1990) J. Mol. Biol. 215:403-410).

[0071] The relationship between a target mRNA (sense strand) and one strand of an siRNA (the sense strand) is that of identity. The sense strand of an siRNA is also called a passenger strand, if present. The relationship between a target mRNA (sense strand) and the other strand of an siRNA (the antisense strand) is that of complementarity. The antisense strand of an siRNA is also called a guide strand.

[0072] The penultimate base in a nucleic acid sequence that is written in a 5' to 3' direction is the next to the last base, i.e., the base next to the 3' base. The penultimate 13 bases of a nucleic acid sequence written in a 5' to 3' direction are the last 13 bases of a sequence next to the 3' base and not including the 3' base. Similarly, the penultimate 14, 15, 16, 17, or 18 bases of a nucleic acid sequence written in a 5' to 3' direction are the last 14, 15, 16, 17, or 18 bases of a sequence, respectively, next to the 3' base and not including the 3' base.

[0073] In an embodiment of the invention, the region of contiguous nucleotides is a region of at least 13 contiguous nucleotides having at least 90% sequence complementarity to, or at least 90% sequence identity with, the penultimate 13 nucleotides of the 3' end of an mRNA corresponding to the sequence identified by each sequence identifier.

[0074] In one embodiment of the invention, the region of contiguous nucleotides is a region of at least 14 contiguous nucleotides having at least 85% sequence complementarity to, or at least 85% sequence identity with, the penultimate 14 nucleotides of the 3' end of an mRNA corresponding to the sequence identified by each sequence identifier. Two nucleotide substitutions (i.e., 12/14=86% identity/complementarity) are included in such a phrase.

[0075] In a further embodiment of the invention, the region of contiguous nucleotides is a region of at least 15, 16, 17, or 18 contiguous nucleotides having at least 80% sequence complementarity to, or at least 80% sequence identity with, the penultimate 14 nucleotides of the 3' end of an mRNA corresponding to the sequence of the sequence identifier. Three nucleotide substitutions are included in such a phrase.

[0076] The target sequence in the mRNAs corresponding to SEQ ID NO:1 or SEQ ID NO:2 may be in the 5' or 3' untranslated regions of the mRNA as well as in the coding region of the mRNA.

[0077] One or both of the strands of double-stranded interfering RNA may have a 3' overhang of from 1 to 6 nucleotides, which may be ribonucleotides or deoxyribonucleotides or a mixture thereof. The nucleotides of the overhang are not base-paired. In one embodiment of the invention, the interfering RNA comprises a 3' overhang of TT or UU. In another embodiment of the invention, the interfering RNA comprises at least one blunt end. The termini usually have a 5' phosphate group or a 3' hydroxyl group. In other embodiments, the antisense strand has a 5' phosphate group, and the sense strand has a 5' hydroxyl group. In still other embodiments, the termini are further modified by covalent addition of other molecules or functional groups.

[0078] The sense and antisense strands of the double-stranded siRNA may be in a duplex formation of two single strands as described above or may be a single molecule where the regions of complementarity are base-paired and are covalently linked by a hairpin loop so as to form a single strand. It is believed that the hairpin is cleaved intracellularly by a protein termed dicer to form an interfering RNA of two individual base-paired RNA molecules.

[0079] Interfering RNAs may differ from naturally-occurring RNA by the addition, deletion, substitution or modification of one or more nucleotides. Non-nucleotide material may be bound to the interfering RNA, either at the 5' end, the 3' end, or internally. Such modifications are commonly designed to increase the nuclease resistance of the interfering RNAs, to improve cellular uptake, to enhance cellular targeting, to assist in tracing the interfering RNA, to further improve stability, or to reduce the potential for activation of the interferon pathway. For example, interfering RNAs may comprise a purine nucleotide at the ends of overhangs. Conjugation of cholesterol to the 3' end of the sense strand of an siRNA molecule by means of a pyrrolidine linker, for example, also provides stability to an siRNA.

[0080] Further modifications include a 3' terminal biotin molecule, a peptide known to have cell-penetrating properties, a nanoparticle, a peptidomimetic, a fluorescent dye, or a dendrimer, for example.

[0081] Nucleotides may be modified on their base portion, on their sugar portion, or on the phosphate portion of the molecule and function in embodiments of the present invention. Modifications include substitutions with alkyl, alkoxy, amino, deaza, halo, hydroxyl, thiol groups, or a combination thereof, for example. Nucleotides may be substituted with analogs with greater stability such as replacing a ribonucleotide with a deoxyribonucleotide, or having sugar modifications such as 2' OH groups replaced by 2' amino groups, 2' O-methyl groups, 2' methoxyethyl groups, or a 2'-O, 4'-C methylene bridge, for example. Examples of a purine or pyrimidine analog of nucleotides include a xanthine, a hypoxanthine, an azapurine, a methylthioadenine, 7-deaza-adenosine and O- and N-modified nucleotides. The phosphate group of the nucleotide may be modified by substituting one or more of the oxygens of the phosphate group with nitrogen or with sulfur (phosphorothioates). Modifications are useful, for example, to enhance function, to improve stability or permeability, or to direct localization or targeting.

[0082] There may be a region or regions of the antisense interfering RNA strand that is (are) not complementary to a portion of SEQ ID NO:1 or SEQ ID NO:2. Non-complementary regions may be at the 3', 5' or both ends of a complementary region or between two complementary regions.

[0083] Interfering RNAs may be generated exogenously by chemical synthesis, by in vitro transcription, or by cleavage of longer double-stranded RNA with dicer or another appropriate nuclease with similar activity. Chemically synthesized interfering RNAs, produced from protected ribonucleoside phosphoramidites using a conventional DNA/RNA synthesizer, may be obtained from commercial suppliers such as Ambion Inc. (Austin, Tex.), Invitrogen (Carlsbad, Calif.), or Dharmacon (Lafayette, Colo.). Interfering RNAs are purified by extraction with a solvent or resin, precipitation, electrophoresis, chromatography, or a combination thereof, for example. Alternatively, interfering RNA may be used with little if any purification to avoid losses due to sample processing.

[0084] Interfering RNAs can also be expressed endogenously from plasmid or viral expression vectors or from minimal expression cassettes, for example, PCR generated fragments comprising one or more promoters and an appropriate template or templates for the interfering RNA. Examples of commercially available plasmid-based expression vectors for shRNA include members of the pSilencer series (Ambion, Austin, Tex.) and pCpG-siRNA (InvivoGen, San Diego, Calif.). Viral vectors for expression of interfering RNA may be derived from a variety of viruses including adenovirus, adeno-associated virus, lentivirus (e.g., HIV, FIV, and EIAV), and herpes virus. Examples of commercially available viral vectors for shRNA expression include pSilencer adeno (Ambion, Austin, Tex.) and pLenti6/BLOCK-iTTM-DEST (Invitrogen, Carlsbad, Calif.). Selection of viral vectors, methods for expressing the interfering RNA from the vector and methods of delivering the viral vector are within the ordinary skill of one in the art. Examples of kits for production of PCR-generated shRNA expression cassettes include Silencer Express (Ambion, Austin, Tex.) and siXpress (Mirus, Madison, Wis.). A first interfering RNA may be administered via in vivo expression from a first expression vector capable of expressing the first interfering RNA and a second interfering RNA may be administered via in vivo expression from a second expression vector capable of expressing the second interfering RNA, or both interfering RNAs may be administered via in vivo expression from a single expression vector capable of expressing both interfering RNAs.

[0085] Interfering RNAs may be expressed from a variety of eukaryotic promoters known to those of ordinary skill in the art, including pol III promoters, such as the U6 or H1 promoters, or pol II promoters, such as the cytomegalovirus promoter. Those of skill in the art will recognize that these promoters can also be adapted to allow inducible expression of the interfering RNA.

[0086] Hybridization under Physiological Conditions: In certain embodiments of the present invention, an antisense strand of an interfering RNA hybridizes with an mRNA in vivo as part of the RISC complex.

[0087] For example, high stringency conditions could occur at about 50% formamide at 37.degree. C. to 42.degree. C. Reduced stringency conditions could occur at about 35% to 25% formamide at 30.degree. C. to 35.degree. C. Examples of stringency conditions for hybridization are provided in Sambrook, J., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Further examples of stringent hybridization conditions include 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50.degree. C. or 70.degree. C. for 12-16 hours followed by washing, or hybridization at 70.degree. C. in 1.times.SSC or 50.degree. C. in 1.times.SSC, 50% formamide followed by washing at 70.degree. C. in 0.3.times.SSC, or hybridization at 70.degree. C. in 4.times.SSC or 50.degree. C. in 4.times.SSC, 50% formamide followed by washing at 67.degree. C. in 1.times.SSC. The temperature for hybridization is about 5-10.degree. C. less than the melting temperature (T.sub.m) of the hybrid where T.sub.m is determined for hybrids between 19 and 49 base pairs in length using the following calculation: T.sub.m.degree. C.=81.5+16.6(log.sub.10 [Na+])+0.41 (% G+C)-(600/N) where N is the number of bases in the hybrid, and [Na+] is the concentration of sodium ions in the hybridization buffer.

[0088] The above-described in vitro hybridization assay provides a method of predicting whether binding between a candidate siRNA and a target will have specificity. However, in the context of the RISC complex, specific cleavage of a target can also occur with an antisense strand that does not demonstrate high stringency for hybridization in vitro.

[0089] Single-stranded interfering RNA: As cited above, interfering RNAs ultimately function as single strands. Single-stranded (ss) interfering RNA has been found to effect mRNA silencing, albeit less efficiently than double-stranded RNA. Therefore, embodiments of the present invention also provide for administration of a ss interfering RNA that hybridizes under physiological conditions to a portion of SEQ ID NO:1 or SEQ ID NO:2 and has a region of at least near-perfect contiguous complementarity of at least 19 nucleotides with the hybridizing portion of SEQ ID NO:1 or SEQ ID NO:2, respectively. The ss interfering RNA of Table 1 or Table 2 has a length of 19 to 49 nucleotides as for the ds interfering RNA cited above. The ss interfering RNA has a 5' phosphate or is phosphorylated in situ or in vivo at the 5' position. The term "5' phosphorylated" is used to describe, for example, polynucleotides or oligonucleotides having a phosphate group attached via ester linkage to the C5 hydroxyl of the sugar (e.g., ribose, deoxyribose, or an analog of same) at the 5' end of the polynucleotide or oligonucleotide.

[0090] SS interfering RNAs are synthesized chemically or by in vitro transcription or expressed endogenously from vectors or expression cassettes as for ds interfering RNAs. 5' Phosphate groups may be added via a kinase, or a 5' phosphate may be the result of nuclease cleavage of an RNA. Delivery is as for ds interfering RNAs. In one embodiment, ss interfering RNAs having protected ends and nuclease resistant modifications are administered for silencing. SS interfering RNAs may be dried for storage or dissolved in an aqueous solution. The solution may contain buffers or salts to inhibit annealing or for stabilization.

[0091] Hairpin interfering RNA: A hairpin interfering RNA is a single molecule (e.g., a single oligonucleotide chain) that comprises both the sense and antisense strands of an interfering RNA in a stem-loop or hairpin structure (e.g., a shRNA). For example, shRNAs can be expressed from DNA vectors in which the DNA oligonucleotides encoding a sense interfering RNA strand are linked to the DNA oligonucleotides encoding the reverse complementary antisense interfering RNA strand by a short spacer. If needed for the chosen expression vector, 3' terminal T's and nucleotides forming restriction sites may be added. The resulting RNA transcript folds back onto itself to form a stem-loop structure.

[0092] Mode of administration: Interfering RNA may be delivered via aerosol, buccal, dermal, intradermal, inhaling, intramuscular, intranasal, intraocular, intrapulmonary, intravenous, intraperitoneal, nasal, ocular, oral, otic, parenteral, patch, subcutaneous, sublingual, topical, or transdermal administration, for example.

[0093] Administration may be directly to the eye by ocular tissue administration such as periocular, conjunctival, subtenon, intracameral, intravitreal, intraocular, subretinal, subconjunctival, retrobulbar, intracanalicular, or suprachoroidal administration; by injection, by direct application to the eye using a catheter or other placement device such as a retinal pellet, intraocular insert, suppository or an implant comprising a porous, non-porous, or gelatinous material; by topical ocular drops or ointments; or by a slow release device in the cul-de-sac or implanted adjacent to the sclera (transscleral) or within the eye. Intracameral injection may be through the cornea into the anterior chamber to allow the agent to reach the trabecular meshwork. Intracanalicular injection may be into the venous collector channels draining Schlemm's canal or into Schlemm's canal.

[0094] Administration may be directly to the ear via, for example, topical otic drops or ointments, slow release devices in the ear or implanted adjacent to the ear. Local administration includes otic intramuscular, intratympanic cavity and intracochlear injection routes of administration. Furthermore, agents can be administered to the inner ear by placement of a gelfoam, or similar absorbent and adherent product, soaked with the interfering RNA against the window membrane of the middle/inner ear or adjacent structure.

[0095] Administration may be directly to the lungs, via, for example, an aerosolized preparation, and by inhalation via an inhaler or a nebulizer, for example.

[0096] Further modes of administration include tablets, pills, and capsules, all of which are capable of formulation by one of ordinary skill in the art.

[0097] Subject: A subject in need of treatment for a TNF.alpha.-related condition or at risk for developing a TNF.alpha.-related condition is a human or other mammal having a TNF.alpha.-related inflammatory condition or having dry eye or at risk of developing a TNF.alpha.-related inflammatory condition or dry eye. A TNF.alpha.-related inflammatory condition includes, for example, allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, or asthma associated with undesired or inappropriate activity of TNF.alpha. as cited herein.

[0098] Ocular structures associated with a TNF.alpha.-related condition may include the eye, retina, choroid, lens, cornea, trabecular meshwork, iris, optic nerve, optic nerve head, sclera, aqueous chamber, vitreous chamber, ciliary body, or posterior segment, for example.

[0099] Otic structures associated with such disorders may include the inner ear, middle ear, outer ear, tympanic cavity or membrane, cochlea, or Eustachian tube, for example.

[0100] Pulmonary structures associated with such disorders may include the nose, mouth, pharynx, larynx, bronchial tubes, trachea, carina (the ridge separating the opening of the right and left main bronchi), and lungs, particularly the lower lungs, such as bronchioli and alveoli.

[0101] A subject may also be an otic cell, a lung cell, an ocular cell, cell culture, organ or an ex vivo organ or tissue.

[0102] Formulations and Dosage: Pharmaceutical formulations comprise interfering RNAs, or salts thereof, of the invention up to 99% by weight mixed with a physiologically acceptable carrier medium such as water, buffer, saline, glycine, hyaluronic acid, mannitol, and the like.

[0103] Interfering RNAs of the present invention are administered as solutions, suspensions, or emulsions. The following are examples of possible formulations embodied by this invention.

TABLE-US-00009 Amount in weight % Interfering RNA up to 99; 0.1-99; 0.1-50; 0.5-10.0 Hydroxypropylmethylcellulose 0.5 Sodium chloride 0.8 Benzalkonium Chloride 0.01 EDTA 0.01 NaOH/HCl Qs pH 7.4 Purified water (RNase-free) Qs 100 Ml

TABLE-US-00010 Amount in weight % Interfering RNA up to 99; 0.1-99; 0.1-50; 0.5-10.0 Phosphate Buffered Saline 1.0 Benzalkonium Chloride 0.01 Polysorbate 80 0.5 Purified water (RNase-free) q.s. to 100%

TABLE-US-00011 Amount in weight % Interfering RNA up to 99; 0. 1-99; 0.1-50; 0.5-10.0 Monobasic sodium phosphate 0.05 Dibasic sodium phosphate 0.15 (anhydrous) Sodium chloride 0.75 Disodium EDTA 0.05 Cremophor EL 0.1 Benzalkonium chloride 0.01 HCl and/or NaOH pH 7.3-7.4 Purified water (RNase-free) q.s. to 100%

TABLE-US-00012 Amount in weight % Interfering RNA up to 99; 0.1-99; 0.1-50; 0.5-10.0 Phosphate Buffered Saline 1.0 Hydroxypropyl-.beta.-cyclodextrin 4.0 Purified water (RNase-free) q.s. to 100%

[0104] Generally, an effective amount of the interfering RNAs of embodiments of the invention results in an extracellular concentration at the surface of the target cell of from 100 pM to 100 nM, or from 1 nM to 50 nM, or from 5 nM to about 10 nM, or about 25 nM. The dose required to achieve this local concentration will vary depending on a number of factors including the delivery method, the site of delivery, the number of cell layers between the delivery site and the target cell or tissue, whether delivery is local or systemic, etc. The concentration at the delivery site may be considerably higher than it is at the surface of the target cell or tissue. Topical compositions are delivered to the surface of the target organ one to four times per day, or on an extended delivery schedule such as daily, weekly, bi-weekly, monthly, or longer, according to the routine discretion of a skilled clinician. The pH of the formulation is about pH 4-9, or pH 4.5 to pH 7.4.

[0105] Therapeutic treatment of patients with siRNAs directed against TACE mRNA or TNFR1 mRNA is expected to be beneficial over small molecule treatments by increasing the duration of action, thereby allowing less frequent dosing and greater patient compliance.

[0106] An effective amount of a formulation may depend on factors such as the age, race, and sex of the subject, the severity of the TNF.alpha.-related condition, the rate of target gene transcript/protein turnover, the interfering RNA potency, and the interfering RNA stability, for example. In one embodiment, the interfering RNA is delivered topically to a target organ and reaches TACE mRNA- or TNFR1 mRNA-containing tissue at a therapeutic dose thereby ameliorating a TNF.alpha.-related process.

[0107] Acceptable carriers: An acceptable carrier refers to those carriers that cause at most, little to no ocular irritation, provide suitable preservation if needed, and deliver one or more interfering RNAs of the present invention in a homogenous dosage. An acceptable carrier for administration of interfering RNA of embodiments of the present invention include the cationic lipid-based transfection reagents TransIT.RTM.-TKO (Mirus Corporation, Madison, Wis.), LIPOFECTIN.RTM., Lipofectamine, OLIGOFECTAMINE.TM. (Invitrogen, Carlsbad, Calif.), or DHARMAFECT.TM. (Dharmacon, Lafayette, Colo.); polycations such as polyethyleneimine; cationic peptides such as Tat, polyarginine, or Penetratin (Antp peptide); or liposomes. Liposomes are formed from standard vesicle-forming lipids and a sterol, such as cholesterol, and may include a targeting molecule such as a monoclonal antibody having binding affinity for endothelial cell surface antigens, for example. Further, the liposomes may be PEGylated liposomes.

[0108] The interfering RNAs may be delivered in solution, in suspension, or in bioerodible or non-bioerodible delivery devices. The interfering RNAs can be delivered alone or as components of defined, covalent conjugates. The interfering RNAs can also be complexed with cationic lipids, cationic peptides, or cationic polymers; complexed with proteins, fusion proteins, or protein domains with nucleic acid binding properties (e.g., protamine); or encapsulated in nanoparticles. Tissue- or cell-specific delivery can be accomplished by the inclusion of an appropriate targeting moiety such as an antibody or antibody fragment.

[0109] For ophthalmic, otic, or pulmonary delivery, an interfering RNA may be combined with ophthalmologically, optically, or pulmonary acceptable preservatives, co-solvents, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, or water to form an aqueous, sterile suspension or solution. Solution formulations may be prepared by dissolving the interfering RNA in a physiologically acceptable isotonic aqueous buffer. Further, the solutions may include an acceptable surfactant to assist in dissolving the inhibitor. Viscosity building agents, such as hydroxymethyl cellulose, hydroxyethyl cellulose, methylcellulose, polyvinylpyrrolidone, or the like may be added to the compositions of the present invention to improve the retention of the compound.

[0110] In order to prepare a sterile ointment formulation, the interfering RNA is combined with a preservative in an appropriate vehicle, such as mineral oil, liquid lanolin, or white petrolatum. Sterile gel formulations may be prepared by suspending the interfering RNA in a hydrophilic base prepared from the combination of, for example, CARBOPOL.RTM.-940 (BF Goodrich, Charlotte, N.C.), or the like, according to methods known in the art. VISCOAT.RTM. (Alcon Laboratories, Inc., Fort Worth, Tex.) may be used for intraocular injection, for example. Other compositions of the present invention may contain penetration enhancing agents such as cremephor and TWEEN.RTM. 80 (polyoxyethylene sorbitan monolaureate, Sigma Aldrich, St. Louis, Mo.), in the event the interfering RNA is less penetrating in the organ or tissue of interest.

[0111] Kits: Embodiments of the present invention provide a kit that includes reagents for attenuating the expression of an mRNA as cited herein in a cell. The kit contains an siRNA or an shRNA expression vector. For siRNAs and non-viral shRNA expression vectors the kit also may contain a transfection reagent or other suitable delivery vehicle. For viral shRNA expression vectors, the kit may contain the viral vector and/or the necessary components for viral vector production (e.g., a packaging cell line as well as a vector comprising the viral vector template and additional helper vectors for packaging). The kit may also contain positive and negative control siRNAs or shRNA expression vectors (e.g., a non-targeting control siRNA or an siRNA that targets an unrelated mRNA). The kit also may contain reagents for assessing knockdown of the intended target gene (e.g., primers and probes for quantitative PCR to detect the target mRNA and/or antibodies against the corresponding protein for western blots). Alternatively, the kit may comprise an siRNA sequence or an shRNA sequence and the instructions and materials necessary to generate the siRNA by in vitro transcription or to construct an shRNA expression vector.

[0112] A pharmaceutical combination in kit form is further provided that includes, in packaged combination, a carrier means adapted to receive a container means in close confinement therewith and a first container means including an interfering RNA composition and an acceptable carrier. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Printed instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.

[0113] The ability of TACE- or TNFR1-interfering RNA to knock-down the levels of endogenous TACE or TNFR1 expression in, for example, human corneal epithelial cells is evaluated in vitro as follows. Transformed human corneal epithelial cells, for example, the CEPI-17 cell line (Offord et al. (1999) Invest Ophthalmol Vis Sci. 40:1091-1101), are plated 24 h prior to transfection in KGM keratinocyte medium (Cambrex, East Rutherford, N.J.). Transfection is performed using DharmaFECT.TM. 1 (Dharmacon, Lafayette, Colo.) according to the manufacturer's instructions at TACE- or TNFR1-interfering RNA concentrations ranging from 0.1 nM-100 nM. Non-targeting control interfering RNA and lamin A/C interfering RNA (Dharmacon) are used as controls. Target mRNA levels are assessed by qPCR 24 h post-transfection using, for example, TAQMAN.RTM. forward and reverse primers and a probe set that encompasses the target site (Applied Biosystems, Foster City, Calif.). Target protein levels may be assessed approximately 72 h post-transfection (actual time dependent on protein turnover rate) by western blot, for example. Standard techniques for RNA and/or protein isolation from cultured cells are well-known to those skilled in the art. To reduce the chance of non-specific, off-target effects, the lowest possible concentration of TACE- or TNFR1 interfering RNA is used that produces the desired level of knock-down in target gene expression.

[0114] Those of skill in the art, in light of the present disclosure, will appreciate that obvious modifications of the embodiments disclosed herein can be made without departing from the spirit and scope of the invention. All of the embodiments disclosed herein can be made and executed without undue experimentation in light of the present disclosure. The full scope of the invention is set out in the disclosure and equivalent embodiments thereof. The specification should not be construed to unduly narrow the full scope of protection to which the present invention is entitled.

[0115] While a particular embodiment of the invention has been shown and described, numerous variations and alternate embodiments will occur to those skilled in the art. Accordingly, it is intended that the invention be limited only in terms of the appended claims.

[0116] The invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes to the claims that come within the meaning and range of equivalency of the claims are to be embraced within their scope. Further, all published documents, patents, and applications mentioned herein are hereby incorporated by reference, as if presented in their entirety.

EXAMPLE 1

Interfering RNA for Specifically Silencing TNFR1 in GTM-3 Cells

[0117] The present study examines the ability of TNFR1 interfering RNA to knock down the levels of endogenous TNFR1 protein expression in cultured GTM-3 cells.

[0118] Transfection of GTM-3 cells (Pang, I. H. et al., 1994. Curr. Eye Res. 13:51-63) was accomplished using standard in vitro concentrations (0.1-10 nM) of TNFR1 siRNAs, siCONTROL RISC-free siRNA #1, or siCONTROL Non-targeting siRNA #2 (NTC2) and DHARMAFECT.RTM. #1 transfection reagent (Dharmacon, Lafayette, Colo.). All siRNAs were dissolved in 1.times.siRNA buffer, an aqueous solution of 20 mM KCl, 6 mM HEPES (pH 7.5), 0.2 mM MgCl.sub.2. Control samples included a buffer control in which the volume of siRNA was replaced with an equal volume of 1.times.siRNA buffer (-siRNA). Western blots using an anti-TNFR1 antibody (Santa Cruz Biotechnology, Santa Cruz, Calif.) were performed to assess TNFR1 protein expression. The TNFR1 siRNAs are double-stranded interfering RNAs having specificity for the following targets: siTNFR1 #1 targets the sequence CAAAGGAACCUACUUGUAC (SEQ ID NO: 202); siTNFR1 #2 targets the sequence GAGCUUGAAGGAACUACUA (SEQ ID NO: 203); siTNFR1 #3 targets the sequence CACAGAGCCUAGACACUGA (SEQ ID NO: 204); siTNFR1 #4 targets the sequence UCCAAGCUCUACUCCAUUG (SEQ ID NO: 205). As shown by the data in FIG. 1, siTNFR1 #1, siTNFR1 #2, and siTNFR1 #3 siRNAs reduced TNFR1 protein expression significantly at the 10 nM and 1 nM concentrations relative to the control siRNAs, but exhibited reduced efficacy at 0.1 nM. The siTNFR1 #2 and siTNFR1 #3 siRNAs were particularly effective. The siTNFR1 #4 siRNA also showed a concentration dependent reduction in TNFR1 protein expression as expected.

Sequence CWU 1

1

20513572DNAHomo sapiens 1acctgcactt ctgggggcgt cgagcctggc ggtagaatct tcccagtagg cggcgcggga 60gggaaaagag gattgagggg ctaggccggg cggatcccgt cctcccccga tgtgagcagt 120tttccgaaac cccgtcaggc gaaggctgcc cagagaggtg gagtcggtag cggggccggg 180aacatgaggc agtctctcct attcctgacc agcgtggttc ctttcgtgct ggcgccgcga 240cctccggatg acccgggctt cggcccccac cagagactcg agaagcttga ttctttgctc 300tcagactacg atattctctc tttatctaat atccagcagc attcggtaag aaaaagagat 360ctacagactt caacacatgt agaaacacta ctaacttttt cagctttgaa aaggcatttt 420aaattatacc tgacatcaag tactgaacgt ttttcacaaa atttcaaggt cgtggtggtg 480gatggtaaaa acgaaagcga gtacactgta aaatggcagg acttcttcac tggacacgtg 540gttggtgagc ctgactctag ggttctagcc cacataagag atgatgatgt tataatcaga 600atcaacacag atggggccga atataacata gagccacttt ggagatttgt taatgatacc 660aaagacaaaa gaatgttagt ttataaatct gaagatatca agaatgtttc acgtttgcag 720tctccaaaag tgtgtggtta tttaaaagtg gataatgaag agttgctccc aaaagggtta 780gtagacagag aaccacctga agagcttgtt catcgagtga aaagaagagc tgacccagat 840cccatgaaga acacgtgtaa attattggtg gtagcagatc atcgcttcta cagatacatg 900ggcagagggg aagagagtac aactacaaat tacttaatag agctaattga cagagttgat 960gacatctatc ggaacacttc atgggataat gcaggtttta aaggctatgg aatacagata 1020gagcagattc gcattctcaa gtctccacaa gaggtaaaac ctggtgaaaa gcactacaac 1080atggcaaaaa gttacccaaa tgaagaaaag gatgcttggg atgtgaagat gttgctagag 1140caatttagct ttgatatagc tgaggaagca tctaaagttt gcttggcaca ccttttcaca 1200taccaagatt ttgatatggg aactcttgga ttagcttatg ttggctctcc cagagcaaac 1260agccatggag gtgtttgtcc aaaggcttat tatagcccag ttgggaagaa aaatatctat 1320ttgaatagtg gtttgacgag cacaaagaat tatggtaaaa ccatccttac aaaggaagct 1380gacctggtta caactcatga attgggacat aattttggag cagaacatga tccggatggt 1440ctagcagaat gtgccccgaa tgaggaccag ggagggaaat atgtcatgta tcccatagct 1500gtgagtggcg atcacgagaa caataagatg ttttcaaact gcagtaaaca atcaatctat 1560aagaccattg aaagtaaggc ccaggagtgt tttcaagaac gcagcaataa agtttgtggg 1620aactcgaggg tggatgaagg agaagagtgt gatcctggca tcatgtatct gaacaacgac 1680acctgctgca acagcgactg cacgttgaag gaaggtgtcc agtgcagtga caggaacagt 1740ccttgctgta aaaactgtca gtttgagact gcccagaaga agtgccagga ggcgattaat 1800gctacttgca aaggcgtgtc ctactgcaca ggtaatagca gtgagtgccc gcctccagga 1860aatgctgaag atgacactgt ttgcttggat cttggcaagt gtaaggatgg gaaatgcatc 1920cctttctgcg agagggaaca gcagctggag tcctgtgcat gtaatgaaac tgacaactcc 1980tgcaaggtgt gctgcaggga cctttctggc cgctgtgtgc cctatgtcga tgctgaacaa 2040aagaacttat ttttgaggaa aggaaagccc tgtacagtag gattttgtga catgaatggc 2100aaatgtgaga aacgagtaca ggatgtaatt gaacgatttt gggatttcat tgaccagctg 2160agcatcaata cttttggaaa gtttttagca gacaacatcg ttgggtctgt cctggttttc 2220tccttgatat tttggattcc tttcagcatt cttgtccatt gtgtggataa gaaattggat 2280aaacagtatg aatctctgtc tctgtttcac cccagtaacg tcgaaatgct gagcagcatg 2340gattctgcat cggttcgcat tatcaaaccc tttcctgcgc cccagactcc aggccgcctg 2400cagcctgccc ctgtgatccc ttcggcgcca gcagctccaa aactggacca ccagagaatg 2460gacaccatcc aggaagaccc cagcacagac tcacatatgg acgaggatgg gtttgagaag 2520gaccccttcc caaatagcag cacagctgcc aagtcatttg aggatctcac ggaccatccg 2580gtcaccagaa gtgaaaaggc tgcctccttt aaactgcagc gtcagaatcg tgttgacagc 2640aaagaaacag agtgctaatt tagttctcag ctcttctgac ttaagtgtgc aaaatatttt 2700tatagatttg acctacaaat caatcacagc ttgtattttg tgaagactgg gaagtgactt 2760agcagatgct ggtcatgtgt ttgaacttcc tgcaggtaaa cagttcttgt gtggtttggc 2820ccttctcctt ttgaaaaggt aaggtgaagg tgaatctagc ttattttgag gctttcaggt 2880tttagttttt aaaatatctt ttgacctgtg gtgcaaaagc agaaaataca gctggattgg 2940gttatgaata tttacgtttt tgtaaattaa tcttttatat tgataacagc actgactagg 3000gaaatgatca gttttttttt atacactgta atgaaccgct gaatatgagg catttggcat 3060ttatttgtga tgacaactgg aatagttttt tttttttttt tttttttttg ccttcaacta 3120aaaacaaagg agataaatct agtatacatt gtctctaaat tgtgggtcta tttctagtta 3180ttacccagag tttttatgta gcagggaaaa tatatatcta aatttagaaa tcatttgggt 3240taatatggct cttcataatt ctaagactaa tgctctctag aaacctaacc acctacctta 3300cagtgagggc tatacatggt agccagttga atttatggaa tctaccaact gtttagggcc 3360ctgatttgct gggcagtttt tctgtatttt ataagtatct tcatgtatcc ctgttactga 3420tagggataca tgctcttaga aaattcacta ttggctggga gtggtggctc atgcctgtaa 3480tcccagcact tggagaggct gaggttgcgc cactacactc cagcctgggt gacagagtga 3540gactctgcct caaaaaaaaa aaaaaaaaaa aa 357222236DNAHomo sapiens 2gctgttgcaa cactgcctca ctcttcccct cccaccttct ctcccctcct ctctgcttta 60attttctcag aattctctgg actgaggctc cagttctggc ctttggggtt caagatcact 120gggaccaggc cgtgatctct atgcccgagt ctcaaccctc aactgtcacc ccaaggcact 180tgggacgtcc tggacagacc gagtcccggg aagccccagc actgccgctg ccacactgcc 240ctgagcccaa atgggggagt gagaggccat agctgtctgg catgggcctc tccaccgtgc 300ctgacctgct gctgccactg gtgctcctgg agctgttggt gggaatatac ccctcagggg 360ttattggact ggtccctcac ctaggggaca gggagaagag agatagtgtg tgtccccaag 420gaaaatatat ccaccctcaa aataattcga tttgctgtac caagtgccac aaaggaacct 480acttgtacaa tgactgtcca ggcccggggc aggatacgga ctgcagggag tgtgagagcg 540gctccttcac cgcttcagaa aaccacctca gacactgcct cagctgctcc aaatgccgaa 600aggaaatggg tcaggtggag atctcttctt gcacagtgga ccgggacacc gtgtgtggct 660gcaggaagaa ccagtaccgg cattattgga gtgaaaacct tttccagtgc ttcaattgca 720gcctctgcct caatgggacc gtgcacctct cctgccagga gaaacagaac accgtgtgca 780cctgccatgc aggtttcttt ctaagagaaa acgagtgtgt ctcctgtagt aactgtaaga 840aaagcctgga gtgcacgaag ttgtgcctac cccagattga gaatgttaag ggcactgagg 900actcaggcac cacagtgctg ttgcccctgg tcattttctt tggtctttgc cttttatccc 960tcctcttcat tggtttaatg tatcgctacc aacggtggaa gtccaagctc tactccattg 1020tttgtgggaa atcgacacct gaaaaagagg gggagcttga aggaactact actaagcccc 1080tggccccaaa cccaagcttc agtcccactc caggcttcac ccccaccctg ggcttcagtc 1140ccgtgcccag ttccaccttc acctccagct ccacctatac ccccggtgac tgtcccaact 1200ttgcggctcc ccgcagagag gtggcaccac cctatcaggg ggctgacccc atccttgcga 1260cagccctcgc ctccgacccc atccccaacc cccttcagaa gtgggaggac agcgcccaca 1320agccacagag cctagacact gatgaccccg cgacgctgta cgccgtggtg gagaacgtgc 1380ccccgttgcg ctggaaggaa ttcgtgcggc gcctagggct gagcgaccac gagatcgatc 1440ggctggagct gcagaacggg cgctgcctgc gcgaggcgca atacagcatg ctggcgacct 1500ggaggcggcg cacgccgcgg cgcgaggcca cgctggagct gctgggacgc gtgctccgcg 1560acatggacct gctgggctgc ctggaggaca tcgaggaggc gctttgcggc cccgccgccc 1620tcccgcccgc gcccagtctt ctcagatgag gctgcgcccc tgcgggcagc tctaaggacc 1680gtcctgcgag atcgccttcc aaccccactt ttttctggaa aggaggggtc ctgcaggggc 1740aagcaggagc tagcagccgc ctacttggtg ctaacccctc gatgtacata gcttttctca 1800gctgcctgcg cgccgccgac agtcagcgct gtgcgcgcgg agagaggtgc gccgtgggct 1860caagagcctg agtgggtggt ttgcgaggat gagggacgct atgcctcatg cccgttttgg 1920gtgtcctcac cagcaaggct gctcgggggc ccctggttcg tccctgagcc tttttcacag 1980tgcataagca gttttttttg tttttgtttt gttttgtttt gtttttaaat caatcatgtt 2040acactaatag aaacttggca ctcctgtgcc ctctgcctgg acaagcacat agcaagctga 2100actgtcctaa ggcaggggcg agcacggaac aatggggcct tcagctggag ctgtggactt 2160ttgtacatac actaaaattc tgaagttaaa gctctgctct tggaaaaaaa aaaaaaaaaa 2220aaaaaaaaaa aaaaaa 2236319DNAArtificialTarget Sequence 3gctctcagac tacgatatt 19421DNAArtificialSense Strand with 3'NN 4gcucucagac uacgauauun n 21521DNAArtificialAntisense strand with 3'NN 5aauaucguag ucugagagcn n 21621RNAArtificialSense Strand 6gcucucagac uacgauauuu u 21721RNAArtificialAntisense Strand 7aauaucguag ucugagagcu u 21819RNAArtificialSense Strand 8gcucucagac uacgauauu 19919RNAArtificialAntisense Strand 9aauaucguag ucugagagc 191048DNAArtificialHairpin duplex with loop 10gcucucagac uacgauauun nnnnnnnaau aucguagucu gagagcuu 481125DNAArtificialSense Strand 11gcucucagac uacgauauuc ucucu 251225RNAArtificialSense Strand 12gcucucagac uacgauauuc ucucu 251327RNAArtificialAntisense Strand 13agagagaaua ucguagucug agagcuu 271419DNAArtificialTarget Sequence 14ccagcagcat tcggtaaga 191519DNAArtificialTarget Sequence 15cagcagcatt cggtaagaa 191619DNAArtificialTarget Sequence 16agcagcattc ggtaagaaa 191719DNAArtificialTarget Sequence 17agagatctac agacttcaa 191819DNAArtificialTarget Sequence 18gaaagcgagt acactgtaa 191919DNAArtificialTarget Sequence 19ccatgaagaa cacgtgtaa 192019DNAArtificialTarget Sequence 20gaagaacacg tgtaaatta 192119DNAArtificialTarget Sequence 21atcatcgctt ctacagata 192219DNAArtificialTarget Sequence 22agagcaattt agctttgat 192319DNAArtificialTarget Sequence 23ggtttgacga gcacaaaga 192419DNAArtificialTarget Sequence 24tgatccggat ggtctagca 192519DNAArtificialTarget Sequence 25gcgatcacga gaacaataa 192619DNAArtificialTarget Sequence 26gcagtaaaca atcaatcta 192719DNAArtificialTarget Sequence 27caatctataa gaccattga 192819DNAArtificialTarget Sequence 28tttcaagaac gcagcaata 192919DNAArtificialTarget Sequence 29ttcaagaacg cagcaataa 193019DNAArtificialTarget Sequence 30tcaagaacgc agcaataaa 193119DNAArtificialTarget Sequence 31tcatgtatct gaacaacga 193219DNAArtificialTarget Sequence 32acagcgactg cacgttgaa 193319DNAArtificialTarget Sequence 33gattaatgct acttgcaaa 193419DNAArtificialTarget Sequence 34ctggagtcct gtgcatgta 193519DNAArtificialTarget Sequence 35tggagtcctg tgcatgtaa 193619DNAArtificialTarget Sequence 36ggagtcctgt gcatgtaat 193719DNAArtificialTarget Sequence 37catgtaatga aactgacaa 193819DNAArtificialTarget Sequence 38ctatgtcgat gctgaacaa 193919DNAArtificialTarget Sequence 39caaatgtgag aaacgagta 194019DNAArtificialTarget Sequence 40gcatcggttc gcattatca 194119DNAArtificialTarget Sequence 41atcggttcgc attatcaaa 194219DNAArtificialTarget Sequence 42ccaagtcatt tgaggatct 194319DNAArtificialTarget Sequence 43ccggtcacca gaagtgaaa 194419DNAArtificialTarget Sequence 44aaaggctgcc tcctttaaa 194519DNAArtificialTarget Sequence 45tttaaactgc agcgtcaga 194619DNAArtificialTarget Sequence 46agatgctggt catgtgttt 194719DNAArtificialTarget Sequence 47atgctggtca tgtgtttga 194819DNAArtificialTarget Sequence 48tgctggtcat gtgtttgaa 194919DNAArtificialTarget Sequence 49ctggtcatgt gtttgaact 195019DNAArtificialTarget Sequence 50tgtaatgaac cgctgaata 195119DNAArtificialTarget Sequence 51gtaatgaacc gctgaatat 195219DNAArtificialTarget Sequence 52ctaagactaa tgctctcta 195319DNAArtificialTarget Sequence 53agactaatgc tctctagaa 195419DNAArtificialTarget Sequence 54cctaaccacc taccttaca 195519DNAArtificialTarget Sequence 55tacatggtag ccagttgaa 195619DNAArtificialTarget Sequence 56tggtagccag ttgaattta 195719DNAArtificialTarget Sequence 57tttatggaat ctaccaact 195819DNAArtificialTarget Sequence 58ggaatctacc aactgttta 195919DNAArtificialTarget Sequence 59accaggccgt gatctctat 196019DNAArtificialTarget Sequence 60aattcgattt gctgtacca 196119DNAArtificialTarget Sequence 61tcgatttgct gtaccaagt 196219DNAArtificialTarget Sequence 62acaaaggaac ctacttgta 196319DNAArtificialTarget Sequence 63gaacctactt gtacaatga 196419DNAArtificialTarget Sequence 64ctacttgtac aatgactgt 196519DNAArtificialTarget Sequence 65tgtgagagcg gctccttca 196619DNAArtificialTarget Sequence 66tcaggtggag atctcttct 196719DNAArtificialTarget Sequence 67caggtggaga tctcttctt 196819DNAArtificialTarget Sequence 68agaaccagta ccggcatta 196919DNAArtificialTarget Sequence 69gaaccagtac cggcattat 197019DNAArtificialTarget Sequence 70aaccagtacc ggcattatt 197119DNAArtificialTarget Sequence 71ccggcattat tggagtgaa 197219DNAArtificialTarget Sequence 72cggcattatt ggagtgaaa 197319DNAArtificialTarget Sequence 73agcctggagt gcacgaagt 197419DNAArtificialTarget Sequence 74ctcctcttca ttggtttaa 197519DNAArtificialTarget Sequence 75ttggtttaat gtatcgcta 197619DNAArtificialTarget Sequence 76gtttaatgta tcgctacca 197719DNAArtificialTarget Sequence 77tttaatgtat cgctaccaa 197819DNAArtificialTarget Sequence 78agtccaagct ctactccat 197919DNAArtificialTarget Sequence 79gagcttgaag gaactacta 198019DNAArtificialTarget Sequence 80cttgaaggaa ctactacta 198119DNAArtificialTarget Sequence 81ttgaaggaac tactactaa 198219DNAArtificialTarget Sequence 82acaagccaca gagcctaga 198319DNAArtificialTarget Sequence 83tgtacgccgt ggtggagaa 198419DNAArtificialTarget Sequence 84ccgttgcgct ggaaggaat 198519DNAArtificialTarget Sequence 85tctaaggacc gtcctgcga 198619DNAArtificialTarget Sequence 86ctaatagaaa cttggcact 198719DNAArtificialTarget Sequence 87taatagaaac ttggcactc 198819DNAArtificialTarget Sequence 88aatagaaact tggcactcc 198919DNAArtificialTarget Sequence 89atagaaactt ggcactcct 199019DNAArtificialTarget Sequence 90tagaaacttg gcactcctg 199119DNAArtificialTarget Sequence 91atagcaagct gaactgtcc 199219DNAArtificialTarget Sequence 92tagcaagctg aactgtcct 199319DNAArtificialTarget Sequence 93agcaagctga actgtccta 199419DNAArtificialTarget Sequence 94gcaagctgaa ctgtcctaa 199519DNAArtificialTarget Sequence 95tgaactgtcc taaggcagg 199619DNAArtificialTarget Sequence 96caaaggaacc tacttgtac 199719DNAArtificialTarget Sequence 97gagcttgaag gaactacta 199819DNAArtificialTarget Sequence 98cacagagcct agacactga 199919DNAArtificialTarget Sequence 99tccaagctct actccattg 1910019DNAArtificialTarget Sequence 100tggagctgtt ggtgggaat 1910119DNAArtificialTarget Sequence 101gacagggaga agagagata 1910219DNAArtificialTarget Sequence 102gggagaagag agatagtgt 1910319DNAArtificialTarget Sequence 103gagaagagag atagtgtgt 1910419DNAArtificialTarget Sequence 104gaagagagat agtgtgtgt

1910519DNAArtificialTarget Sequence 105gtgtgtgtcc ccaaggaaa 1910619DNAArtificialTarget Sequence 106gaaaatatat ccaccctca 1910719DNAArtificialTarget Sequence 107aaatatatcc accctcaaa 1910819DNAArtificialTarget Sequence 108ctgtaccaag tgccacaaa 1910919DNAArtificialTarget Sequence 109accaagtgcc acaaaggaa 1911019DNAArtificialTarget Sequence 110ccaagtgccacaaaggaac 1911119DNAArtificialTarget Sequence 111ccacaaaggaacctacttg 1911219DNAArtificialTarget Sequence 112caaaggaacc tacttgtac 1911319DNAArtificialTarget Sequence 113aaaggaacct acttgtaca 1911419DNAArtificialTarget Sequence 114gatacggact gcagggagt 1911519DNAArtificialTarget Sequence 115cggactgcag ggagtgtga 1911619DNAArtificialTarget Sequence 116tccttcaccg cttcagaaa 1911719DNAArtificialTarget Sequence 117cagaaaacca cctcagaca 1911819DNAArtificialTarget Sequence 118tgcctcagct gctccaaat 1911919DNAArtificialTarget Sequence 119ctccaaatgc cgaaaggaa 1912019DNAArtificialTarget Sequence 120tccaaatgccgaaaggaaa 1912119DNAArtificialTarget Sequence 121ccaaatgccg aaaggaaat 1912219DNAArtificialTarget Sequence 122gccgaaagga aatgggtca 1912319DNAArtificialTarget Sequence 123aggaaatggg tcaggtgga 1912419DNAArtificialTarget Sequence 124ggaaatgggt caggtggag 1912519DNAArtificialTarget Sequence 125gtgtgtggct gcaggaaga 1912619DNAArtificialTarget Sequence 126ggaagaacca gtaccggca 1912719DNAArtificialTarget Sequence 127ccatgcaggt ttctttcta 1912819DNAArtificialTarget Sequence 128catgcaggtt tctttctaa 1912919DNAArtificialTarget Sequence 129tgcaggtttc tttctaaga 1913019DNAArtificialTarget Sequence 130aggtttcttt ctaagagaa 1913119DNAArtificialTarget Sequence 131ggtttctttc taagagaaa 1913219DNAArtificialTarget Sequence 132agagaaaacg agtgtgtct 1913319DNAArtificialTarget Sequence 133gagtgtgtct cctgtagta 1913419DNAArtificialTarget Sequence 134ctgtagtaac tgtaagaaa 1913519DNAArtificialTarget Sequence 135agaaaagcct ggagtgcac 1913619DNAArtificialTarget Sequence 136ttgagaatgt taagggcac 1913719DNAArtificialTarget Sequence 137tgttaagggc actgaggac 1913819DNAArtificialTarget Sequence 138ggtcattttc tttggtctt 1913919DNAArtificialTarget Sequence 139cctcctcttc attggttta 1914019DNAArtificialTarget Sequence 140tcctcttcat tggtttaat 1914119DNAArtificialTarget Sequence 141ctcttcattg gtttaatgt 1914219DNAArtificialTarget Sequence 142tcttcattgg tttaatgta 1914319DNAArtificialTarget Sequence 143cttcattggt ttaatgtat 1914419DNAArtificialTarget Sequence 144tccaagctct actccattg 1914519DNAArtificialTarget Sequence 145ctccattgtt tgtgggaaa 1914619DNAArtificialTarget Sequence 146gggaaatcga cacctgaaa 1914719DNAArtificialTarget Sequence 147tgaaggaact actactaag 1914819DNAArtificialTarget Sequence 148acctccagct ccacctata 1914919DNAArtificialTarget Sequence 149cccacaagcc acagagcct 1915019DNAArtificialTarget Sequence 150acgccgtggt ggagaacgt 1915119DNAArtificialTarget Sequence 151ggaaggaatt cgtgcggcg 1915219DNAArtificialTarget Sequence 152tgagcgacca cgagatcga 1915319DNAArtificialTarget Sequence 153gcgaggcgca atacagcat 1915419DNAArtificialTarget Sequence 154tgggctgcct ggaggacat 1915519DNAArtificialTarget Sequence 155catcaagtac tgaacgttt 1915619DNAArtificialTarget Sequence 156tcgtggtggt ggatggtaa 1915719DNAArtificialTarget Sequence 157gaaagcgagt acactgtaa 1915819DNAArtificialTarget Sequence 158gagcctgact ctagggttc 1915919DNAArtificialTarget Sequence 159ccacataaga gatgatgat 1916019DNAArtificialTarget Sequence 160cataagagat gatgatgtt 1916119DNAArtificialTarget Sequence 161cgaatataac atagagcca 1916219DNAArtificialTarget Sequence 162gttaatgata ccaaagaca 1916319DNAArtificialTarget Sequence 163ctgaagatat caagaatgt 1916419DNAArtificialTarget Sequence 164atgaagagtt gctcccaaa 1916519DNAArtificialTarget Sequence 165atgaagaaca cgtgtaaat 1916619DNAArtificialTarget Sequence 166aattattggt ggtagcaga 1916719DNAArtificialTarget Sequence 167atcatcgctt ctacagata 1916819DNAArtificialTarget Sequence 168atacatgggc agaggggaa 1916919DNAArtificialTarget Sequence 169gggcagaggg gaagagagt 1917019DNAArtificialTarget Sequence 170ggaagagagt acaactaca 1917119DNAArtificialTarget Sequence 171gaagagagta caactacaa 1917219DNAArtificialTarget Sequence 172gagagtacaa ctacaaatt 1917319DNAArtificialTarget Sequence 173gctaattgac agagttgat 1917419DNAArtificialTarget Sequence 174cggaacactt catgggata 1917519DNAArtificialTarget Sequence 175ggataatgca ggttttaaa 1917619DNAArtificialTarget Sequence 176aggctatgga atacagata 1917719DNAArtificialTarget Sequence 177gaatacagat agagcagat 1917819DNAArtificialTarget Sequence 178ggtaaaacct ggtgaaaag 1917919DNAArtificialTarget Sequence 179gtgaaaagca ctacaacat 1918019DNAArtificialTarget Sequence 180gaggaagcat ctaaagttt 1918119DNAArtificialTarget Sequence 181tatgggaact cttggatta 1918219DNAArtificialTarget Sequence 182tgacgagcac aaagaatta 1918319DNAArtificialTarget Sequence 183gcacaaagaa ttatggtaa 1918419DNAArtificialTarget Sequence 184ggttacaact catgaattg 1918519DNAArtificialTarget Sequence 185actcatgaat tgggacata 1918619DNAArtificialTarget Sequence 186gtggcgatca cgagaacaa 1918719DNAArtificialTarget Sequence 187ctataagacc attgaaagt 1918819DNAArtificialTarget Sequence 188gaacgcagca ataaagttt 1918919DNAArtificialTarget Sequence 189gcaataaagt ttgtgggaa 1919019DNAArtificialTarget Sequence 190caataaagtt tgtgggaac 1919119DNAArtificialTarget Sequence 191gagggtggat gaaggagaa 1919219DNAArtificialTarget Sequence 192ggatgaagga gaagagtgt 1919319DNAArtificialTarget Sequence 193gcatcatgta tctgaacaa 1919419DNAArtificialTarget Sequence 194caggaaatgc tgaagatga 1919519DNAArtificialTarget Sequence 195gaatggcaaa tgtgagaaa 1919619DNAArtificialTarget Sequence 196ggatgtaatt gaacgattt 1919719DNAArtificialTarget Sequence 197gtggataaga aattggata 1919819DNAArtificialTarget Sequence 198ggataaacag tatgaatct 1919919DNAArtificialTarget Sequence 199cctttaaact gcagcgtca 1920019DNAArtificialTarget Sequence 200cgtgttgaca gcaaagaaa 1920119DNAArtificialTarget Sequence 201gcaaagaaac agagtgcta 1920219RNAArtificialTarget Sequence 202caaaggaacc uacuuguac 1920319RNAArtificialTarget Sequence 203gagcuugaag gaacuacua 1920419RNAArtificialTarget Sequence 204cacagagccu agacacuga 1920519RNAArtificialTarget Sequence 205uccaagcucu acuccauug 19

Claims

1. An interfering RNA for inhibiting the expression of a tumor necrosis factor .alpha. receptor-1 (TNFR1) gene wherein the interfering RNA comprises a sense strand and an antisense strand each 19-49 nucleotides in length, wherein the sense strand comprises a nucleotide sequence of any of SEQ ID NO:59-SEQ ID NO:154, SEQ ID NO:202-SEQ ID NO:204 except that the T's can be T's or U's and the antisense strand comprises a nucleotide sequence that is complementary to any of SEQ ID NO:59-SEQ ID NO:154, SEQ ID NO:202-SEQ ID NO:204.

2. The compositions of claim 1, wherein each strand of the interfering RNA molecule is 19 to 27 nucleotides in length.

3. The interfering RNA of claim 1 wherein the interfering RNA comprises one or more chemically modified nucleotides, one or more deoxyribonucleotides, and/or one or more non-phosphodiester linkages.

4. The interfering RNA of claim 3 wherein the chemically modified nucleotides independently contain 2' amino groups, 2' O-methyl groups, or 2' methoxyethyl groups,

5. The interfering RNA of claim 3 wherein the interfering RNA comprises one or more chemically modified nucleotides and one or more non-phosphodiester linkages.

6. The interfering RNA of claim 3 wherein non-nucleotide material is bound to the 5' end and/or 3' end of the sense strand and/or the antisense strand.

7. The interfering RNA of claim 3 wherein the non-nucleotide material is bound internally to the sense strand and/or the antisense strand.

8. The interfering RNA of claim 6 wherein the non-nucleotide material improves cellular uptake, enhances cellular targeting, assists in tracing, improves stability, and/or reduces activation of the interferon pathway.

9. The interfering RNA of claim 3 wherein the sense strand and/or the antisense strand contains a 3' overhang.

10. The interfering RNA of claim 3 wherein the sense strand and/or the antisense strand contains a 5' overhang.

11. The interfering RNA of claim 3, wherein the interfering RNA molecule at least one blunt end.

12. The interfering RNA of claim 3, wherein, the sense strand comprises a nucleotide sequence of SEQ ID NO:204 or SEQ ID NO:205 except that the T's can be T's or U's, and the antisense strand comprises a nucleotide sequence that is complementary SEQ ID NO:204 or SEQ ID NO:205.

13. A composition for inhibiting the expression of a tumor necrosis factor .alpha. receptor-1 (TNFR1) comprising an interfering RNA wherein the interfering RNA comprises a sense strand and an antisense strand, the sense strand comprises a nucleotide sequence of any of SEQ ID NO:59-SEQ ID NO:154, SEQ ID NO:202-SEQ ID NO:204 except that the T's can be T's or U's and the antisense strand comprises a nucleotide sequence that is complementary to any of SEQ ID NO:59-SEQ ID NO:154, SEQ ID NO:202-SEQ ID NO:204 and a pharmaceutically acceptable carrier.

14. The composition of claim 13 wherein the interfering RNA comprises one or more chemically modified nucleotides, one or more deoxyribonucleotides, and/or one or more non-phosphodiester linkages.

15. The composition of claim 14 wherein the chemically modified nucleotides are independently contain 2' amino groups, 2' O-methyl groups, or 2' methoxyethyl groups,

16. The composition of claim 14 wherein the interfering RNA comprises one or more chemically modified nucleotides and one or more non-phosphodiester linkages.

17. The composition of claim 14 wherein non-nucleotide material is bound to the 5' end and/or 3' end of the sense strand and/or the antisense strand.

18. The composition of claim 14 wherein the non-nucleotide material is bound internally to the sense strand and/or the antisense strand.

19. The composition of claim 17 wherein the non-nucleotide material improves cellular uptake, enhances cellular targeting, assists in tracing, improves stability, and/or reduces activation of the interferon pathway.

20. The composition of claim 14 wherein the sense strand and/or the antisense strand contains a 3' overhang.

21. The composition of claim 14 wherein the sense strand and/or the antisense strand contains a 5' overhang.

22. The composition of claim 14, wherein the interfering RNA molecule at least one blunt end.

23. An interfering RNA for inhibiting the expression of a tumor necrosis factor .alpha. receptor-1 (TNFR1) wherein the interfering RNA comprises a sense strand and an antisense strand, wherein said antisense strand is complementary to any of SEQ ID NO: 3, SEQ ID NOs:14-58 or SEQ ID NOs:155-201.